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1Introduction
Prion diseases or transmissible spongiform encephalopathies (TSEs) are fatal neu-
rodegenerative disorders (198). The crucial event in the development of these
diseases is the conformational change of a membrane bound protein, the cellular
PrPC in Figure 3.1, into a disease associated, fibril-forming isoform (199).
Despite their rare incidence, TSEs have captured very large attention from the
scientific community due to the unorthodox mechanism by which prion diseases
are transmitted. Increasing evidence supports the hypothesis that the infectious
agent, responsible for the propagation of TSEs, is the prion or PrP Sc, which
propagates itself by imposing its conformation onto its non pathogenic isoform,
the host cellular prion protein, PrPC (147; 199) (see Figure 1.1).
PrPC belongs to the class of amyloid-forming proteins which are associated
with a variety of conformational diseases (52; 76).1 Actually, inducible pro-
teinopathies such as amyloid AA amyloidosis (239) and Alzheimers (168), turn
out to share remarkable similarities to prion diseases (239). Hence, studying the
key molecular mechanisms involved in prion diseases may help to understand
these other amyloidoses. 2
1These include Alzheimers disease, Parkinsons disease, Huntingtons disease, spinocerebellar
ataxias, type II diabetes, amyotrophic lateral sclerosis, as well as diffuse Lewy body dementia
and fronto-temporal dementias.
2We further notice that the striking parallels of infectious prion disorders to the above-
mentioned putatively non- infectious protein misfolding and assembly diseases make it more
difficult to delimitate their pathological mechanisms from each other.
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Figure 1.1: The Human Prion Protein - The mature human prion protein
features two signal peptides (1-23 and 231-235), an octapeptide repeat region (in-
volved in binding Cu2+ ions (169)), three α-helixes, one disulphide bond (SS)
between cysteine residues 179 and 214, and two potential sites for N-linked gly-
cosylation (green forks) at residues 181 and 197. A glycosylphosphatidylinositol
anchor (GPI) (yellow box) is attached to the C-terminus of PrPC .
2
Little information is available about the infection mechanism by which prion
diseases are transmitted. In particular, neither the structural determinants of
PrP Sc nor the in vivo conditions which lead to formation of PrP Sc, are known.
So far, the tendency of PrPC to undergo induced or spontaneous misfolding
has been related to its amino acid sequence (224), to the presence of a highly
flexible amino term (196), to the proteins secondary structure elements (2) as
well as to the proteins post-translational modifications (206).1 Most importantly,
a relationship between point mutations and TSEs has been firmly established
(34; 90; 204; 230). Indeed, in the presence of specific disease-linked mutations,
the PrPC → PrP Sc conversion appears to occur spontaneously (13; 220; 223).
The mutations increase the kinetics of the misfolding process relative to WT
(220), possibly mostly because of a destabilization of the native structure and/or
increasing the stability of the partially folded intermediate species (13; 150; 220;
223).
Hence, investigating the intrinsic instability of PrPC fold mutants is key for
TSEs research.
The PrPC → PrP Sc pathogenic conversion process, enhanced by specific
mutations, has been related to the global conformational fluctuations of the pro-
tein (138; 139). NMR has provide extremely accurate information on structure
and conformational properties of proteins involved in neurodegenerative diseases,
including prions (38; 54; 55; 73; 92; 113; 115; 153; 203; 204; 236; 247; 252).
However, the very large number of disease-linked variants (more than 30), only
very few of them have been characterized by NMR so far (115; 252).
Molecular Dynamic (MD) simulations have been successfully used to inves-
tigate structure and dynamics of a variety of proteins undergoing fibrillation
(65; 68; 79; 104; 125; 156; 174; 190; 192; 233; 250), including the prion protein
(94; 118; 143; 194; 208; 253). Hence, such computational approach appears ideal
to complement NMR studies in the understanding how disease-linked mutations
affect structure and dynamics of the prion protein.
We have therefore decided to carry out MD calculations on all of the disease-
linked mutations of the structural domain of the protein (90 % of the total number
1Metal ions (53) and cellular protein partners (101; 119) are also thought to be involved in
the structural determination of PrP.
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of disease-linked mutations), for which the NMR structure is available. We have
built a computational protocol able to predict structural facet as well as confor-
mational properties of such variants. The protocol has been validated by NMR
experimental data (including those obtained during my thesis by Prof. Legname’s
Lab (115). Our calculations shed light on common structural traits across the
mutants which could play a role for the fibrillation process.
Small ligands have shown to have the opposite effect than disease-linked mu-
tations, as they may decrease in the Gibbs free energy of PrPC upon binding
(Fig. 1.2) (58; 140; 246). In addition, they may suppress conformational rear-
rangements leading to the PrPC → PrP Sc conversion by cross-linking of distant
regions (30; 140; 246). Hence, they might counter react the tendency towards
aggregation of the disease-linked mutations as well as the WT. 1 To identify bind-
ing poses, molecular docking methodologies are well suited (103). Unfortunately
these approaches, whilst fast and useful for enzymes and receptors, are likely to
fail here because of the lack of a well-defined binding cavity: only shallow binding
sites are present in the structure, as shown in an elegant NMR study by Kuwata
and co-workers (140).
Prompted by the relevance of this issue, I tried to establish a computational
approach that attempts to include conformational selection (29) and induced fit
(132) processes, which play an important role for ligand binding. The work has
been done in collaboration with my colleagues Agata Kranjc, Salvatore Bon-
garzone and Xevi Biarns. We focus on the ligand (2-pyrrolidin-1-yl-N-[4-[4-(2-
pyrrolidin-1-yl-acetylamino)-benzyl]-phenyl]-acetamide), for which the free en-
ergy of binding to the prion protein has been measured (140). Our protocol in-
cludes standard docking methods, Molecular Dynamic (MD) and metadynamics-
based (141) free energy simulations in explicit solvent. After an educated guess
of the ligand poses using standard docking programs, we have relaxed the lig-
and/target complex by MD, and sorting out the poses by their binding energy
using metadynamics-based (141) free energy calculations. The method follows
previous molecular docking approaches designed to account for protein flexibility
(11; 36; 47; 227). It then adds a further step by using the metadynamics ap-
proach to evaluate poses and potency of the ligand. The accuracy of the protocol
1This strategy is applicable regardless of the disease etiology (58).
4
is established by a comparison not only with thermodynamic data (140) but also
with qualitative structural insights obtained by NMR (140).
Figure 1.2: PrPC to PrPSc conversion - Qualitative scheme illustrating the
Gibbs free energy change in the interconversion, as proposed by Prusiner et al.
(199). The interconversion is thought to entail intermediate partially folded con-
formers (58; 139). The mutation could destabilize PrPC (hence increasing the
population of intermediates), whilst small ligands may stabilize the PrPC confor-
mation (and hence reduce the population of intermediates species) (139; 220).
5

2Materials & methods
2.1 Biomolecular Simulations
”Certainly no subject or field is making more progress on so many fronts at the present moment,
than biology, and if we were to name the most powerful assumption of all, which leads one on
and on in an attempt to understand life, it is that all things are made of atoms, and that
everything that living things do can be understood in terms of the jigglings and wigglings of
atoms.”
Richard P. Feynman from Six easy pieces 1963
These words were pronounced about 50 years ago and discussion is still open. How can
we ’see’ this wiggling and jiggling and understand how it drives biology? Can we believe in
modeling?
These are a question often asked by biologists and biochemists. Giving an answer requires
not only the understanding of the strengths and limitations of current computational biomolec-
ular modeling and simulation methods, but also their ranges of application. The scepticism
encountered among experimentalists of all biomolecular modeling is sometimes misplaced; nev-
ertheless equally misguided is a blind acceptance of modeling results without critical analysis.
Biomolecular modeling is a fertile and growing area, with exciting opportunities and poten-
tial applications. It is crucial for the biomolecular modeler to understand the issues of interest
to biologists; but more important is to understand the complexity of biological systems and how
to tackle them effectively by modeling. Vast amounts of data are being provided by large-scale
research efforts in genomics, proteomics, glycomics and structural biology. The challenge for
biomolecular modeling is to help in efforts to use these diverse data to develop new drugs, thera-
pies, catalysts and biologically based nanotechnology. (231) Increasingly, computer simulations
of biological macromolecules are helping to meet this challenge. In particular, molecular simu-
lations have been more and more being employed to investigate features not directly accessible
to experiments. Whereas it is indeed possible to take ”still snapshots” of crystal structures and
7
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probe features of the motion of molecules through NMR, no current experimental technique
allows access to all the time scales of motion with atomic resolution. Simulations based on fun-
damental physics offer the potential of filling-in these crucial ’gaps’, modeling how proteins and
other biomolecules move, fluctuate, interact, react and function. Applications include studies
of protein folding and conformational changes, association of proteins with small molecules or
other proteins, structure-based drug design, computation of binding free energies for ligands,
modeling the dynamics of ion channels and transport across membranes and modeling and
analysis of enzyme mechanisms.
Improvements in computer hardware continue to deliver more computational power, which,
when combined with theoretical and algorithmic developments, have led to an increasing range
and depth of applications of molecular modeling and molecular dynamic in biology. Molecular
dynamics (MD) is a specialized computer-based discipline to simulate time evolving atomistic
or molecular systems. In such simulations, motion of atoms is determined within the framework
of classical mechanics.
A huge part of this thesis benefits of MD techniques and all the results obtained are con-
stantly related with experimental data. Thus, it is crucial to establish relationships between
experiments and molecular simulations, and between macroscopic and microscopic world. In
the following paragraph I will explain this issues.
2.2 From Microscopic to Macroscopic: Simula-
tions as a bridge between theory and exper-
iments.
An experiment is usually made on a macroscopic sample that contains an extremely large num-
ber of atoms or molecules sampling an enormous number of conformations. On the other hand
computer simulations generate information at the microscopic level, including atomic positions
and velocities. The conversion of this microscopic information to macroscopic observables such
as pressure, energy, heat capacities, etc., requires statistical mechanics.
2.2.1 Statistical Mechanics.
Statistical mechanics is fundamental to the study of biological systems by molecular dynamics
simulations because it provides the rigorous mathematical expressions that relate macroscopic
properties to the distribution and motion of the atoms and the molecules of the N-body system;
computer simulations provide instead the means to solve the equation of motion.
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2.2 From Microscopic to Macroscopic: Simulations as a bridge
between theory and experiments.
Definitions: thermodynamic state and microscopic state.
The thermodynamic state of a system is usually defined by a set of parameters (state variables)
that are physical observables, like for example, the temperature, T, the pressure, P, and the
number of particles, N.
The mechanical or microscopic state of a system is defined by the atomic positions, q, and
momenta, p; these can also be considered as coordinates in a multidimensional space called
phase space (Γ). A single point in phase space, denoted by G, describes the state of the system.
Thus, the macroscopic or thermodynamic state (macrostate) described by thermodynamic
quantities, is statistically interpreted in terms of all the accessible microscopic mechanical states
(microstates) where each is characterized by all the N atoms positions,
(q1,q2,..., qN ) ≡ qN
, and momenta,
(p1,p2,..., pN ) ≡ pN
, i.e., points in the multidimensional phase space Γ.
An ensemble is a collection of points in phase space satisfying the conditions of a particular
thermodynamic state. Or we can also say that it is a collection of all possible systems, which
have different microscopic states but have an identical macroscopic or thermodynamic state.
Common techniques to sample the configurations assumed by a system at equilibrium are
Molecular Dynamics (MD), Monte Carlo (MC) sampling and Stochastic/Brownian dynamics.
A MD simulation generates a sequence of points in phase space as a function of time; these
points belong to the same ensemble, and they correspond to the different conformations of the
system and their respective momenta. Thermodynamic quantities are determined in computer
simulations as ensemble averages over a large number of microscopic configurations assumed
by the system under study. This is allowed due to the ergodic hypothesis assumption.
2.2.2 Calculating Averages from a Molecular Dynamics
Simulation: the Ergodic hypothesis.
In statistical mechanics, averages corresponding to experimental observables are defined in
terms of ensemble averages. Indeed thermodynamic observables can be alternatively modeled
by considering at once a collection of identical systems. Each system represents one of all the
accessible microstates. If this collection (statistical ensemble) is allowed to evolve in time, its
behavior can be characterized by a time dependent distribution function, (qN(t), pN(t)) for
the microstates. The instantaneous average value of the observable, O, over the phase space is
interpreted as: ∫
Γ
O(qN (t)pN (t))ρ(qN (t)pN (t))dqNdpN∫
Γ
ρ(qN (t)pN (t))dqNdpN
(eq.1)
9
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If we assume equal probability for all microstates, then the distribution of points in phase space
is frozen into one single shape, i.e., the distribution function is time invariant, and the condition:
ρ(qN (t)pN (t))dqNdpN
dt
= 0 (eq.2)
describes the thermodynamic equilibrium and the so-called ensemble average is defined as:
〈O〉ensemble =
∫
Γ
O(qN (t)pN (t))ρ(qN (t)pN (t))dqNdpN∫
Γ
ρ(qN (t)pN (t))dqNdpN
(eq.3)
In a molecular dynamics simulation, the points in the ensemble are calculated sequentially in
time, thus, assuming that the equations of motion of the system are solved, each observable can
be empirically associated with a function (O), of the instantaneous microstate, (qN (t), pN (t)), of
the system. Nevertheless, the quantity O(qN (t), pN (t)) is not an observable since measurements
are performed in a macroscopic time; thus any microscopic observable is assumed to be a time
averaged value:
〈O〉ensemble = limτ→∞
∫ τ0+t
τ0
O(qN (t)pN (t))dt (eq.4)
The ergodic hypothesis states that in thermodynamic equilibrium, the time average
and the ensemble average are equal.
That is, if one allows the system to evolve indefinitely in time, the system will pass through
all possible microstates, and the experimental measurement will coincide with the calculated
time and ensemble averages.
Such a procedure is well founded only for the so-called ergodic systems, which are assumed to
fully sample the accessible phase space (hyper)volume during the observation (i.e. simulation)
time. It is generally assumed that complex systems, such as the majority of those biologically
relevant, are ergodic. Although this is a plausible assumption, it should be pointed out that
the ergodic hypothesis is not always true (for some example see e.g. Ref. (84)).
2.2.3 Trajectory Accuracy: Shadow Orbits and the Lia-
punov instability.
A further drawback affecting (in principle) all kinds of MD simulations is the so-called Liapunov
instability (? ):
Two trajectories differing initially by an infinitesimal amount (∆x) will diverge exponen-
tially in time: ∆x(t) = ∆x(0)exp(λt).
Hamiltonian systems, with very few exceptions, are chaotic.
For chaotic systems, like almost all those simulated by MD, the trajectory is extremely
sensitive to initial conditions. Any error in the integration of the equation of motion, no matter
how small, will always cause the simulated (numerical) trajectory to diverge exponentially from
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the true trajectory starting from the same initial conditions. Thus, any imperfect integrator
(and all are imperfect) introduces errors that guarantee the trajectory diverges from the true
trajectory. How can we know that we are generating the correct results in MD? In some cases,
there is actually a shadow orbit that closely follows the integrated trajectory. Or from other
point of view, the true trajectory, to which the numerical one overlaps for a certain period of
time, is called shadow orbit 1. The shadow orbit is an exact trajectory for the system, but it
starts from a slightly displaced initial point. At the time the Liapunov instability raises up,
the numerical trajectory will get far from that specific shadow orbit, but there always will be
another one of these to which it is superimposed.
Thus, even if the numerical trajectory diverges from the true one, as long as it conserves
the total energy E within a given accuracy ∆E, the sampled configurations will belong to a
constant energy hypersurface E∗ for which |E∗ − E| < ∆E. This means that the numerical
trajectory will be, within the error ∆E, representative of some true trajectory in the phase
space, although it is not known a priori which one.
Figure 2.1: Shadow Orbit - Schematic representation of a Shadow Orbit
2.2.4 How Long? How Large?
Molecular dynamics evolves a finite-sized molecular configuration forward in time, in a step-
by-step fashion. There are limits on the typical time scales and length scales that can be
investigated and the consequences must be considered in analyzing the results.
2.2.4.1 Correlation Time and Correlation Length.
Simulation runs are typically short corresponding to few nanoseconds of real time, and in special
cases extending to the microsecond regime. This means that we need to test whether or not a
1These are known to exist for hyperbolic systems. Can sometimes be shown to exist, for
long times, for more general systems [e.g., see Quinlan and Tremaine, Mon. Not. R. Astron.
Soc. 259, 5050 (1992)].
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simulation has reached equilibrium before we can trust the averages calculated in it. Moreover,
there is a clear need to subject the simulation averages to a statistical analysis, to make a
realistic estimate of the errors. How long should we run? This depends on the system and
the physical properties of interest. If we have an observable a, the time correlation function is
〈a(t0)a(t0 + t)〉; assuming that the system is in equilibrium, this function is independent of the
choice of time origin and may be written 〈a(0)a(t)〉. From eq.4 we can easily define a correlation
time
τa =
τ∫
0
dt 〈a(0)a(t)〉 / 〈a2〉 (eq.5)
for which the measure of a(0) and a(t) became uncorrelated. At the same way, we can define
a spatial correlation function 〈a(0)a(t)〉 relating values computed at different points r apart.
Spatial isotropy allows us to write this as a function of the distance between the points, r, rather
than the vector r: notably this symmetry is broken in a liquid crystal. Spatial homogeneity,
which applies to simple liquids (but not to solids or liquid crystals) allows us to omit any
reference to an absolute origin of coordinates. This function decays from a short-range nonzero
value to zero over a characteristic distance ξa, the correlation length. It is almost essential for
simulation box sizes to be large compared with ξa, and for simulation run lengths τ to be large
compared with τa, for all properties of interest a. Only when these two conditions are respected
it is guaranteed that reliably-sampled statistical properties are obtained.
2.2.4.2 Accessible time and length scale
An important issue of simulation studies is the accessible time and length scale coverable by
microscopic simulations. Figure 2.2 shows a schematic representation for different types of
simulations in a length-time-diagram. It is clear that the more detailed a simulation technique
operates, the smaller is the accessibility of long times and large length scales. Therefore quantum
simulations, where fast motions of electrons are taken into account, are located in the lower
left corner of the diagram and typical length and time scales are of order of and ps. Classical
molecular dynamics approximates electronic distributions in a rather coarse-grained fashion by
putting either fixed partial charges on interaction sites or by adding an approximate model for
polarization effects. In both cases, the time scale of the system is not dominated by the motion of
electrons, but by the time of intermolecular collision events, rotational motions or intramolecular
vibrations, which are orders of magnitude slower than those of electron motions. Consequently,
the time step of integration is larger and trajectory lengths are of order ns and accessible lengths
of order 10100 A. If tracer particles in a solvent medium are considered, Brownian dynamics can
be applied, where the effect of the solvent is hidden in average quantities. Since collision times
between tracer particles is very long, larger time steps may be applied. Furthermore, since the
solvent is not simulated explicitly, the length scales may be increased considerably. Finally,
if one is interested not in a microscopic picture of the simulated system but in macroscopic
quantities, the concepts of hydrodynamics may be applied, where the system properties are
hidden in effective numbers, e.g. density, viscosity, sound velocity.
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Figure 2.2: Time and Lenght scales - Schematic comparison of time and
length scales, accessible to different types of simulation techniques (quantum sim-
ulations (QM), molecular dynamics (MD), Brownian dynamics (BD) and hydro-
dynamics/fluid dynamics (HD)).
2.2.5 Design a Molecular Dynamic Simulation in biomolec-
ular fields.
A key decision in beginning a simulation of a biomolecular system is the choice of an appropriate
method for that particular system and for the questions of interest. A modeling method should
be capable of delivering a reliable result in a reasonable time(231).
Studies involving multi-nanosecond dynamics simulations are now common. However, ex-
pert knowledge is still required, and care needs to be taken to ensure that the application of a
biomolecular simulation method to a particular problem is meaningful and useful.
Concerning MD simulations the ingredients are basically three:
1. A model for the interaction between system constituents (atoms, molecules, surfaces
etc.) is needed.
2. An integrator is needed, which propagates particle positions and velocities from time t
to t + δt. It is a finite difference scheme that moves trajectories discretely in time. The time
step t has properly to be chosen to guarantee stability of the integrator, i.e. there should be no
drift in the systems energy.
3. A statistical ensemble has to be chosen, where thermodynamic quantities like pressure,
temperature or the number of particles are controlled. The natural choice of an ensemble in
MD simulations is the microcanonical ensemble (NVE), since the systems Hamiltonian without
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external potentials is a conserved quantity. Nevertheless, there are extensions to the Hamilto-
nian, which also allow simulating different statistical ensembles.
These choices essentially define an MD simulation.
Molecular dynamics simulation used in this thesis are perfomed with a classical description
of the system under study (point 1) and the use of Gromacs simulation Package (27; 107) (point
2) in the NPT ensemble (point 3). I will define the interaction model and the ensemble chosen
in the following paragraphs.
2.3 Classical Molecular Dynamics Simulations
2.3.1 Introduction
Molecular systems and motion of their constituents, both nuclei and electrons, are known to be
accurately described only by laws of quantum mechanics. Implementation of classical laws of
mechanics in this scheme involves a series of approximations for the quantum description:
1- The molecular wavefunction (solution) of the molecular Schrdinger equation is separated
into nuclear and electronic parts according to Born-Oppenheimer approximation, so that
motion of nuclei is decoupled from electronic motion due to the fact that nuclei are much heav-
ier. Such decoupling allows their equations of motion to be separated and solved.
2- Nuclei are approximated as classical particles.
3- Third, electronic variables could be either integrated out beforehand and an approximate
single potential energy surface (usually representing the electronic ground state) is constructed;
or they could be treated within a suitable approximation as active degrees of freedom via the
electronic Schrdinger equation, and forces on nuclei are computed by electronic structure cal-
culations that are performed for each generated trajectory.
Accordingly to how the electronic part is treated, MD simulation is branched out into two
methodologies:
• Classical Molecular Dynamics, where forces are derived from predefined potential models
by analytical gradient applications.
• Ab initio Molecular Dynamics, where forces on nuclei are obtained from the electronic
structure calculations.
I will describe only the classical molecular dynamic approach.
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2.3.2 Derivation of classical molecular dynamics equations.
A molecular system with the positions of N nuclei, R = {R1, R2..., RN}, and the n elec-
trons located at r = {r1, r2..., rn}, is completely described non relativistically by the molecular
Schrdinger equation:
i~
∂
∂t
Φ(r,R; t) = HΦ(r,R; t) (eq.6)
Where H is the non-relativistic molecular Hamiltonian, in SI units, of the N nuclei and n
electrons. In absence of external fields, it has the form:
H(R, r) = −
N∑
i=1
~
2MI
∇2RI −
n∑
i=1
~
2Me
∇2ri +
N,N−1∑
I=1,J>1
ZiZje
2
4piε0|RI−RJ |+
n,n−1∑
i=1,j>1
e2
4piε0|ri−rj |+
N,n∑
I=1,i=1
ZIe
2
4piε0|RI−ri|
(eq.7)
Where MI is the mass of nucleus I whose atomic number is ZI , me is the mass of the
electron, and e is its charge. The operator ∆RI and ∆ri act on the coordinates nucleus I and
electron i respectively. Thus we can write as:
H(R, r) = TN (R) + Te(r) + V (r,R) = TR(R) +He(r,R)
The electron-nucleus interactions bind electrons to nuclei, and leads to a mathematical insepa-
rable Hamiltonian.
At room temperature the thermal wavelength λ is about 0.1 A, while typical interatomic
distances, in liquids and solids, are of the order of 1 A. Thus, a good approximation is to
neglect quantum correlations between wave functions of different nuclei, i.e to consider the
nuclear wavefunction as an incoherent superimposition of individual nuclear wave packets. In
addition, nuclear masses are large enough that such individual wave packets are usually well
localized. Formally, we can separate electronic from nuclear degrees of freedom by writing
the wavefunction as product of terms depending only on electronic or nuclear positions (”one-
determinant” Ansatz):
Φ(r,R;T ) ≈ Ψ(r; t)χ(R; t) exp
1
~
t∫
t0
dt′Ee(t′)
 (eq.8)
where the electronic and nuclear wavefunctions are separately normalized:
〈Ψ(r; t) | Ψ(r; t)〉 = 1, 〈χ(R; t) | χ(R; t)〉 = 1
and the phase factor has the form:∫
drdRΨ∗(r; t)χ∗(R; t)HeΨ(r; t)χ(R; t)
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Inserting this last expression in Schrdinger equation, multiply from left by 〈Ψ(r; t)| and 〈χ(R; t)|,
integrate over R and r, and apply the energy conservation:
d
dt
∫
Φ∗(r,R; t)HΦ(r,R; t) = 0
the following system of coupled equations is obtained:
i~
∂Ψ
∂t
= −
∑ ~
2me
∇2riΨ +
{∫
drdRχ∗(R; t)V (r,R)χ(R; t)
}
Ψ (eq.9)
i~
∂χ
∂t
= −
∑ ~
2MI
∇2RIχ+
{∫
drdRΨ∗(r; t)HeΨ(r; t)
}
χ (eq.10)
which defines the basis of the TDSCF, method introduced as early as 1930 by Dirac.
Each wavefunction above obey Schrdinger equation but with time dependent effective po-
tential obtained by appropriate averages over the other degrees of freedom; both electrons and
nuclei move quantummechanically in timedependent effective potentials (or selfconsistently ob-
tained average fields) obtained from appropriate averages (quantum mechanical expectation
values 〈...〉) over the other class of degrees of freedom. The next step in the derivation of
classical molecular dynamics is the task to approximate the nuclei as classical point par-
ticles. A classical description of nuclei dynamics is achieved by expressing χ in terms of an
amplitude factor A and a phase S which are both considered to be real and A > 0 in this polar
representation:
χ(R; t) = A(R; t) exp
[
iS(R; t)
~
]
(eq.11)
Using the polar representation, in the classical limit ~ → 0, on the eq.9 and 10, the following
set of equations is obtained:
∂S
∂t
+
N∑
I=1
(∇IS)2
2MI
+
∫
drΨ∗HeΨ = 0 (eq.12)
∂A2
∂t
+
N∑
I=1
∇ ·
(
A2
∇IS
MI
)
= 0 (eq.13)
The equation for A is a continuity equation for the density probability A2 = |χ|2 of nuclei,
which move with classical velocities ∇IS/MI = pI/MI .
More important for our purpose is the equation eq.12 . Indeed, if we use the connection
PI ≡ ∇IS, it becomes isomorphic to the Hamilton-Jacobi equation of classical motion for action
S and Hamiltonian H(R,P)=T(P)+V(R) defined in terms of (generalized) coordinates {RI}
and their conjugate momenta {PI}. The Newtonian equation of motion P˙I = −∇IV ({RI})
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corresponds to eq.12:
dPI
dt = −∇I
∫
drΨ∗HeΨ
or
MIR¨I(t) = −∇I
∫
drΨ∗HeΨ
(eq.14)
Thus, the nuclei move according to classical mechanics in an effective potential V Ee due to the
electrons. This potential is a function of only the nuclear positions at time t as a result of
averaging He over the electronic degrees of freedom, i.e. computing its quantum expectation
value 〈Ψ|He |Ψ〉, while keeping the nuclear positions fixed at their instantaneous values RI(t).
In other words, nuclei are driven by a mean-field potential due to electrons and containing
also a contribution from their kinetic energy. Finally, to get off the nuclear wavefunction also
from eq. 9 one replaces the nuclear density |χ({RI(t)}; t)|2 by a product of delta functions∏
I δ(RI −RI(t)), i.e. incoherent wave packets extremely localized [46]. At the classical limit,
the electronic wave equation is:
i~
∂Ψ
∂t
= −
∑
i
~2
2me
∇2riΨ + V (r,R(t))Ψ (eq.15)
which evolves selfconsistently as the classical nuclei are propagated via eq. 14. Note that now
He and thus depend parametrically on the classical nuclear positions {RI(t)} at time t through
V Ee ({RI(t)}) . These equations represent the so called ”Ehrenfest molecular dynamics” scheme.
It is clear now that the motion of the nuclei is dictated by the Hamiltonian He, which basically
contains the quantistic information on the electronic system. Although the TDSCF approach
underlying Ehrenfest molecular dynamics clearly is a meanfield theory, transitions between
electronic states are included in this scheme. Thus, at this stage a further simplification can be
invoked by restricting the total electronic wave function Ψ to be the ground state wave function
Ψ0 of He at each instant of time. This should be a good approximation if the energy difference
between Ψ0 and the first excited state Ψ1 is everywhere large compared to the thermal energy
kBT , roughly speaking.
In this limit the nuclei move on a single potential energy surface:
V Ehre =
∫
drΨ∗0HeΨ0 ≡ E0({RI(t)}) (eq.16)
which is computed by solving the electronic time-independent Schrdinger equation only for the
ground state:
HeΨ0 = E0Ψ0 (eq.17)
Now, E0 is a function of nuclear positions R, and both Ehrenfest and the ground state Born-
Oppenheimer potentials are identical.
As a consequence of this observation, it is conceivable to decouple the task of generating
the nuclear dynamics from the task of computing the potential energy surface. Assuming the
possibility to solve the stationary Schrdinger equation for as many nuclear configurations as
possible, the classical molecular dynamics approach is derived by the following three steps
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scheme:
1. Solving eq. 17 for many representative nuclear configurations to compute the ground
state energy E0.
2. The generated data points R, V Ehr(R) or some equivalent experimental data points are
fitted to a suitable analytical functional form to construct a global potential energy surface.
3. The following Newtonian equation of motion:
MIR¨I(t) = −∇IV Ehre ({RI(t)}) (eq.18)
is solved by applying analytically the gradient for many different initial conditions to produce
the nuclear classical trajectories on this global potential energy surface.
Furthermore the overall internal interaction potential is approximated to V appr which is ex-
panded to pair-wise, three-body, four-body and up to n-body contributions, these contributions
are categorized as intermolecular long-range and intramolecular short-range interaction:
V Ehr ≈ V appr(R) =
N∑
I<J
VIJ(RIRJ)+
N∑
I<J<K
VIJK(RIRJRK)+
N∑
I<J<K<L
VIJKL(RIRJRKRL)+...
(eq.19)
Potential expansion is practically truncated at some term to reduce the dimensionality resulting
from the increase of the number of active nuclear degrees of freedom. Within the same poten-
tial expansion, electronic degrees of freedom do no longer appear explicitly but are effectively
included in a functional form of V appr potential.
As a result of this derivation, the essential assumptions underlying classical molecular dy-
namics become transparent: the electrons follow adiabatically the classical nuclear motion and
can be integrated out so that the nuclei evolve on a single BornOppenheimer potential energy
surface (typically but not necessarily given by the electronic ground state), which is in general
approximated in terms of fewbody interactions.
2.4 Empirical Force Fields
As relevant biological processes usually involve large systems (thousands of atoms or more),
and occur in relatively long timescales (from nano to microseconds or more), it is necessary
to develop effective parametrized potentials, which are faster to integrate, albeit less accurate,
in order to study this kind of systems. The term force field indicates a functional form for
this approximation, which relates the configuration of the system ({Ri}, i = 1, ..., N) to its
internal energy U, along with the set of parameters used in that function. In this work, the
AMBER(188) force field for description of macromolecules in solution has been used, while the
GROMACS(27; 107) package has been used to integrate the equation of motion. The functional
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form can be written as:
U =
∑
bonds
Kr(r − req)2 +
∑
angles
Kθ(θ − θeq)2 +
∑
dihedrals
Vn
2 [1 + cos(nϕ− γ)]+
+
∑
i<j
[
4εij
(
σij
rij
)12
−
(
σij
rij
)6
+ qiqjεrij
] (eq.20)
Atom bond stretching and angle bending are represented as harmonic terms, while dihe-
drals or torsional are described by a sinusoidal term. Non-bonded interactions comprise two
terms, the first is a Lennard-Jones 6-12 which describes atom-atom repulsion and dispersion
interactions, the second is the Coulomb electrostatic term. In eq. eq.20, r and θ are respectively
the bond length and valence angle; φ is the dihedral or torsion angle and rij is the distance
between atoms i and j. Parameters include the bond force constant and equilibrium distance,
Kr and req, respectively; the valence angle force constant and equilibrium angle, Kθ, and θeq,
respectively; the dihedral force constant, multiplicity and phase angle, Vn, n, and γ, respec-
tively. The functional form used for out-of-plane distorsions (e.g. in planar groups) is different
in different force fields. For instance, in the AMBER force field this term has the same form
as that used for proper dihedrals, while in CHARMM an harmonic term is used. Collectively,
these parameters represent the internal or intramolecular ones.
Non bonded parameters between atoms i and j include the partial atomic charges, qi, along
with the LJ well-depth, ij , and σij , the (finite) distance at which the inter-particle potential
is zero. These terms are also referred to as the interaction or external parameters. Typically,
ij , and σij are obtained for individual atom types and then combined to yield ij , and σij
for the interacting atoms via combining rules. The dielectric constant  is typically set to 1
(corresponding to the permittivity of vacuum) in calculations that incorporate explicit solvent
representations.
Van der Waals and electrostatic interactions are calculated between atoms belonging to
different molecules or for atoms in the same molecules separated by at least three bonds. For
the van der Waals potential, this truncation introduce only a small error in the energy.
This is not the case for the electrostatic potential, because the Coulomb interaction between
charges qi and qj decays slowly with distance. Hence it can not be truncated, but when periodic
boundary conditions are used, it is computed with efficient schemes such as Particle Mesh Ewald
in conjunction with periodic boundary conditions, which approximate the exact result to an
acceptable error similar to the error in the van der Waals potential.
2.4.1 Long Range Interactions
In simulations of biological systems it is highly convinient to avoid the calculation of all non-
bonded pair interactions, as the computational cost would be proportional to the square of
the number of atoms. These interactions primarily dictates the dynamics of biomolecules, and
cannot be merely truncated beyond a given cutoff when long-ranged. The difference between
short and long interactions is the spatial extent of the potential. If the potential drops down
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to zero faster than rd, where r is the separation between two particles and d the dimension of
the problem, it is called short ranged, otherwise it is long ranged. This becomes clear by
considering the integral:
I =
∫
drd
rn
= {∞ : n ≤ d; finite : n > d
i.e a particles potential energy gets contributions from all particles of the universe if n d,
otherwise the interaction is bound to a certain region, which is often modeled by a spherical
interaction range. Long range interactions essentially require to take all particle pairs into
account for a proper treatment of interactions. Coulomb (∼ φ−1) and dipole-dipole (∼ φ−3)
should be considered long-range when dealing with three-dimensional systems. This may be-
come a problem, if periodic boundary conditions are imposed to the system, i.e. formally
simulating an infinite number of particles (no explicit boundaries imply infinite extent of the
system). Therefore one has to devise special techniques to treat this situation.
2.4.2 Ewald Summation Method
The Ewald summation method originates from the physics of crystals, where the problem was
to determine the Madelung constant, describing a factor for an effective electrostatic energy
in a perfect periodic crystal. Considering the electrostatic energy of a system of particles in
a cubic box and imposing periodic boundary conditions, leads to an equivalent problem. At
position ri of particle i, the electrostatic potential, φ, can be written down as a lattice sum:
ϕ(ri) =
1
8piε0
∞∑
|n|=0
N∑
j=1
qj
|rij + nL|
thus, for N particles:
E =
1
8piε0
∞∑
|n|=0
 N∑
j=1
N∑
j=1
qjqi
|rij + nL|

where L is the length of the periodic box , N is the total number of atoms, and n are the direct
lattice vectors. i is not equal to j for |n| = 0. This equation is conditionally convergent, i.e.
the result of the outcome depends on the order of summation. Moreover, the sum extends
over infinite number of lattice vectors. Thus, the procedure has to be modified in order to
get an absolute convergent sum and to get it fast converging. The original method of Ewald
consisted in introducing a convergence factor e−ns, which makes the sum absolute convergent;
then transforming it into different fast converging terms and then putting s in the convergence
factor to zero. The final result of the calculation can be easier understood from a physical
picture. If every charge in the system is screened by a counter charge of opposite sign, which
is smeared out, then the potential of this composite charge distribution becomes short ranged
(it is similar in electrolytic solutions, where ionic charges are screened by counter charges -
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the result is an exponentially decaying function, the Debye potential). In order to compensate
for the added charge distribution this has to be subtracted again. The far field of a localized
charge distribution is, however, again a Coulomb potential. Therefore this term will be long
ranged. The efficiency gain shows up, when the short range interactions are calculated as direct
particle-particle contributions in real space, while the long range part of the smeared charge
cloud are summed up in reciprocal Fourier space. Choosing as the smeared charge distribution
a Gaussian charge cloud of half width 1/α the corresponding expression for the energy becomes:
ϕ(ri)
∑
n
N∑
j=1
qj
erfc(α |rij + nL|
|rij + nL| +
4pi
L3
∑
k 6=0
N∑
j=1
qj
|k|2 e
−|k|2/4αeikrij − qi 2α√
pi
The parameter tunes the relative weights of real and reciprocal sums, although the final result
is independent of it. An optimal choice for it makes the Ewald sum converge as N3/2, which
can be further improved to NlnN with the use of Particle-Mesh methods (as the Particle-Mesh
Ewald, PME or the Particle-Particle Particle-Mesh, PPPM)(66; 80), making advantage of the
Fast Fourier Transform. The last term corresponds to a self-energy contribution which has to
be subtracted, as it is considered in the Fourier part. The new equation is an exact equivalent
of the first, with the difference that it is an absolute converging expression. Therefore nothing
would be gained without further approximation. Since the complimentary error function can be
approximated for large arguments by a Gaussian function and the k-space parts decreases like
a Gaussian, both terms can be approximated by stopping the sums at a certain lattice vector
n and a maximal kvalue, kmax.
2.4.3 Boundaries
Restriction on the size of a time step is not the only challenge in molecular dynamics methods.
Another concerns the finite size effects of the simulated system as its number of particles is far
fewer than that in any natural sample, and is most from thousands to maximum few millions.
Enclosing the system with a rigid-walled container, most particles would be under the influence
of its boundaries through collisions. If we ignore the boundaries most particles would lie at
surface whose area tends to be minimized, distorting thus the shape of the system whenever
it is a non-spherical. It is of no help to increase particles in a system as the more particles
exist, the more particles are at the surface and more undesired effects are encountered. Those
peculiarity due to the size limit and the improper treatment of boundaries, makes it unreliable
to statistically extract macroscopic bulk properties since the later are calculated in the limit
N → ∞, where N is the number of particles. To go over both practical difficulties, periodic
boundary conditions are imposed on the relatively small systems in such a way that particles
experience forces as if they reside in the bulk.
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Figure 2.3: Periodic boundary conditions. - Periodic boundary conditions.
As a particle moves out of the simulation box, an image particle moves in to replace
it. In calculating particle interactions within the cutoff range, both real and image
neighbours are included.
2.4.3.1 Periodic boundary conditions (PBC)
When applying periodic boundaries, the fundamental (primitive) simulation cell is replicated
infinitely and periodically in all directions. There is no restriction on the shape of the cell other
than having the characteristic to completely fill all of space translationally with no overlaps
nor voids. It is appropriate to choose a cell shape that reflects the underlying geometry of
the system in question. When the interactions are of a short range each side of the replicated
primitive cell must be of a length that is at least twice the radius of the spatial cutoff so to keep
accuracy. Particles in this case are subjected to the condition such that when a particle leaves
the primitive cell, its image from the cell on the opposite side reenters the cell with the same
velocity. Herein, boundaries of the cell are no longer rigid but imaginary and their effects are
completely absent. When subjecting the system to this condition, the system is not any more
invariant (symmetric) under space rotation; henceforth the angular momentum is no longer
conserved whereas the linear momentum and mechanical energy are still conserved.
2.4.3.2 Minimum image convention for short range interactions
For short ranged forces, PBC are used in conjunction with the minimum image convention. In
this scheme each particle interacts at most with only one image of every other particle n the
system. To exclude interactions of a particle with its own images (self-interaction), the assumed
cubic simulation cell, as already mentioned, must have a side length of at least as twice as the
radius of the cutoff. Interactions terms between pairs further away from each other than the
cutoff radius are obviously zero.
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2.4.4 Neighbors List
For short-range potentials, not all the n-permutations represent a set of interacting particles
since particles at a larger separation than a spatial cutoff radius do not interact. Nevertheless
computing the non-bonded contribution to the interatomic forces in an MD simulation involves,
in principle, a large number of pairwise calculations: we consider each atom i and loop over
all other atoms j to calculate the minimum image separations rij. Let us assume that the
interaction potentials are of short range, ν(rij) = 0 if rij > rcut, the potential cutoff. In this
case, the program skips the force calculation, avoiding expensive calculations, and considers
the next candidate j. Nonetheless, the time to examine all pair separations is proportional to
the number of distinct pairs, 1/2 N (N 1) in an N-atom system, and for every pair one must
compute at least r2ij ; this still consumes a lot of time. Some economies result from the use of
lists of nearby pairs of atoms. Verlet suggested such a technique for improving the speed of a
program. The potential cutoff sphere, of radius rcut, around a particular atom, is surrounded
by a skin of rlist radius. At the first step in a simulation, a list is constructed of all the neighbors
of each atom, for which the pair separation is within rlist. Over the next few MD time steps,
only pairs appearing in the list are checked in the force routine. Therefore, in a force routine,
not all particles have to tested, whether they are in a range r < rcut, but only those particle
pairs, stored in the list. Since particles are moving during the simulation, it is necessary to
update the list from time to time. List update must be at the correct frequency, a common
update is between 10 to 20 time steps. To avoid double counting in the energy summation,
only neighbors where (j > 1) are stored. In some cases of three/four body interactions, it is a
must to only exclude equal indices, i.e., the list must contain all the pairs (j 6= 1) for evaluation
of three-body terms defined by the valence bond angle.
2.4.5 Constrains
It is quite common practice in classical computer simulations not to attempt to represent
intramolecular bonds by terms in the potential energy function, because these bonds have very
high vibration frequencies (and arguably should be treated in a quantum mechanical way rather
than in the classical approximation). Instead, the bonds are treated as being constrained to
have fixed length. In classical mechanics, constraints are introduced through the Lagrangian or
Hamiltonian formalisms. The general principle of the formalism is the Hamiltons variational
principle:
Let L be the Lagrangian of the system; Hamiltons principle states that the physical trajec-
tory taken by that system satisfies:
∂
t2∫
t1
Ldt = 0
for any pair of times t1, t2, where variations are taken with respect to q and are fixed at the
endpoints. This means that a trajectory followed by a mechanic system in the phase space is
the one that minimize the integral
∫
Ldt where L is define as L=K-V. Lagrangian formalism
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Figure 2.4: The Verlet list - The Verlet list on its construction, later, and too
late. The potential cutoff range (solid circle), and the list range (dashed circle),
are indicated. The list must be reconstructed before particles originally outside the
list range (black) have penetrated the potential cutoff sphere.
allow to treat constrains in a simply and direct way for system in which constrains are only on
the position (holonomic) and can be written as gl({ri}) = 0. Lagrangian equation becomes:
d
dt
(
∂L
∂r˙i
)
− ∂L
∂ri
=
M∑
l=1
λl
∂gl
∂ri
where M are Lagrange multiplier and l are function of N coordinate and velocities. This means
the right equation part could be considered as a generalized force that produces the same ef-
fects of imposed constrains. It is easy to derive an exact expression for the multiplier M from
the above equations; However, this exact solution is not what we want: in practice, since the
equations of motion are only solved approximately, in discrete time steps, the constraints will
be increasingly violated as the simulation proceeds. The breakthrough in this area came with
the proposal to determine the constraint forces in such a way that the constraints are satis-
fied exactly at the end of each time step. For the original Verlet algorithm, this scheme is
called SHAKE, which calculates the constraint forces λgi necessary to ensure that the end-
of-step positions ri satisfy: gl({ri}) = 0 An alternative constraint method, LINCS (Linear
Constraint Solver) was developed in 1997 by Hess, Bekker, Berendsen and Fraaije(106)LINCS
applies Lagrange multipliers to the constraint forces and solves for the multipliers by using a
series expansion to approximate the inverse of the Jacobian. This approximation only works
for matrices with Eigenvalues smaller than 1, making the LINCS algorithm suitable only for
molecules with low connectivity. It is important to realize that a simulation of a system with
rigidly constrained bond lengths, is not equivalent to a simulation with, for example, harmonic
springs representing the bonds, even in the limit of very strong springs. A subtle, but crucial,
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difference lies in the distribution function for the other coordinates. If we obtain the config-
urational distribution function by integrating over the momenta, the difference arises because
in one case a set of momenta is set to zero, and not integrated, while in the other integration
is performed, which may lead to an extra term depending on particle coordinates. This is
frequently called the metric tensor problem.
2.4.6 MD in NPT Ensemble
The ergodic hypothesis was introduced for a system described by the microcanonical distri-
bution NVE. However, the conditions of constant volume V, number of particles N and total
energy E do not fit those in which experiments are usually made. Thus, it is necessary to define
schemes allowing for the evolution of systems under conditions of constant volume and temper-
ature (NVT ), or constant pressure and temperature (NPT ), corresponding to typical real-life
situations. In this work, the simulations were performed in the NPT ensemble. To simulate
the systems in such ensemble, thermostat and barostat algorithms are required to control the
temperature and pressure during the MD run.
2.4.7 Nose-Hoover thermostat
A way to sample the NVT ensemble within the framework of MD was introduced about twenty
years ago by Nose(180; 181) and reformulated by Hoover. This method modifies Newton
equation of motion by adding two non physical variables, thus introducing the following non-
Hamiltonian dynamical system where there is added a fictitious degree of freedom, with mass
equal to Q. The new extended Hamiltonian has the form:
H∗ =
N∑
i=1
p2i
2mi
+ ϕ(ri) +
Q
2
ζ2 + gkT lnS
where {ri},{pi} are coordinates and momenta of the N particles with masses mi, and S and ζ
are coordinates and momenta of fictitious atoms. If φ is the interaction potential and g are the
degree of freedom, the new equation of motion are:
r˙i = pimi
p˙i = −dϕdt − ζpi
dζ
dt =
P p2i
mi
−gkBT
Q
These equations sample a microcanonical ensemble in the extended system, however, the energy
of the real system is not constant. Nevertheless it can be shown, that the equations of motion
sample a canonical ensemble in the real system. The parameter Q controls the strength of the
coupling to the thermostat: high values result into a low coupling and viceversa. Although
any finite (positive) mass is sufficient to guarantee in principle the generation of a canonical
ensemble, if Q is too large, the canonical distribution will only be obtained after very long
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simulation times. On the other hand, too small values (tight coupling) may cause high-frequency
temperature oscillations.
2.4.8 Berendsen thermostat
A weaker formulation of this approach is the Berendsen thermostat.(25; 26) To maintain the
temperature the system is coupled to an external heat bath with fixed temperature T0. The
velocities are scaled at each step, such that the rate of change of temperature is proportional
to the difference in temperature:
dT (t)
dt
=
1
τ
(T0 − T (t))
where τ is the coupling parameter which determines how tightly the bath and the system are
coupled together. This method gives an exponential decay of the system towards the desired
temperature. The change in temperature between successive time steps is:
∆T =
δt
τ
(T0 − T (t))
Thus, the scaling factor for the velocities is:
λ2 = 1 +
δ
τ
{
T0
T (t− δt/2
}
In practice τ is used as an empirical parameter to adjust the strength of the coupling. Its value
has to be chosen with care. In the limit τ → ∞ the Berendsen thermostat is inactive and the
run is sampling a microcanonical ensemble. The temperature fluctuations will grow until they
reach the appropriate value of a microcanonical ensemble. However, they will never reach the
appropriate value for a canonical ensemble. On the other hand, too small values of τ will cause
unrealistically low temperature fluctuations. If τ is chosen the same as the time step t, the
Berendsen thermostat is nothing else than the simple velocity scaling. Values of τ ≈ 0. 1ps are
typically used in MD simulations of condensed-phase systems. The ensemble generated when
using the Berendsen thermostat is not a canonical ensemble.
The Andersen method(10) was developed to adjust the pressure in a simulation of interact-
ing particles. In the following description, only systems of pairwise inter- acting particles are
treated. The method was later first extended to anisotropic coupling by Parrinello et al.(188)
and later also to molecular systems by Nos et al.(180; 181) Andersen proposed to replace the
coordinates ri by scaled coordinates ρi defined as:
ρi = ri/V 1/3
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Consider the new Lagrangian, in which a new variable Q appears:
L
(
ρN , ρ˙N , Q, Q˙
)
=
1
2
Q2/3
N∑
i=1
miρ˙
2
i −
N∑
i<j
U(Q1/3ρij) +
1
2
MQ˙2 − p0Q
If we interpret Q as the volume V, the first two terms on the right are just the Lagrangian of
the unscaled system. The third term is a kinetic energy for the motion of Q, and the fourth
represent a potential energy associated with Q. Here p0 and M are constants. A physical
interpretation of the additional terms would be: Assume the system is simulated in a container
and can be compressed by a piston. Thus, Q, whose value is the volume V, is the coordinate
of the piston. p0 V is the potential derived from an external pressure p0 acting on the piston
and M is the mass of the piston.
2.4.8.1 Parrinello-Rahman barostat
When simulating crystal structures, it is not sufficient only to scale the volume. Parinello and
Rahman extended the method proposed by Andersen to let the simulation box also change its
shape.(188) Lets start with some notation: The cell can have an arbitrary shape, its volume
completely described by three vectors a,b,c. The vectors can have different lengths and arbitrary
mutual orientations. An alternative description is obtained by arranging the vectors as {a, b, c}
to form a 3 x 3 matrix h whose columns are the latter vectors. The volume is given by:
V = deth = a · (b× C)
The position ri of a particle can be written in terms of h and a column of vector si, with
components ξi, ηi and ζi as:
ri = hsi = ξia+ ηib+ ζic
with 0 ≤ ξi, ηi, ζi ≤ 1. The square of the distance between particle i and j is given by:
r2ij = s
T
ijGsij
where the metric tensor G is G = hTh. Using the latter notation, the Lagrangian can be written
as:
L =
1
2
∑
mis˙
T
i Gs˙i −
∑∑
U(rij) +
1
2
MTr(h˙T h˙) = pV
Deriving the equations of motion is similar to the isotropic case from Andersen.
2.5 Comments on other techniques used.
In the project presented in Chapter 6, part of the calculations was carried out by other mem-
bers of the biomolecular simulation group of SISSA. These are the metadynamics free-energy
calculations which have been performed by Xevi Biarnes and molecular docking which have
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been performed by Agata Kranjc and Salvatore Bongarzone. For this reason the theory of
free-energy calculations and docking is not presented here but in the computational section and
in the Appendix of the corresponding chapter.
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3Prion diseases
3.1 The prion-only hypothesis
Prion diseases, also termed transmissible spongiform encephalopathies (TSEs), are fatal neu-
rodegenerative diseases that affect humans and a wide variety of animals. Human forms of
prion diseases include Creutzfeld-Jacob disease (CJD), Gerstamnn-Straussler-Scheinker disease
(GSS), fatal familial insomnia (FFI) and kuru (see Appendix A), whereas the animal forms
include scrapie (Sc) in sheep and goat, chronic wasting disorder (CWD) in mule, deer and elk,
and bovine spongiform encephalopathy (BSE) in cattle (59; 199; 243).
Prion diseases are generally characterized by widespread neurodegeneration and therefore,
clinically exhibit symptoms of cognitive and motor dysfunction while, pathologically, TSEs are
characterized by neuronal vacuolation, astrocytic gliosis, and amyloid plaques.
Prion diseases may be sporadic (arise spontaneously without any apparent cause), inher-
ited (due to mutations in the gene encoding human prion protein, PRNP) and/or acquired
by the transmission of an infectious agent (199): despite of the common morphological and
pathophysiological features with other progressive encephalopathies, such as Alzheimers and
Parkinsons disorder (6), prion diseases are unique in that they are transmissible. 1. Hence, the
most intriguing aspect of prion diseases is the nature of the infectious pathogen, also referred
to as the scrapie agent. This was termed prion (a small proteinaceous infectious particle that
is resistant to inactivation by most procedures that modify nucleic acids (197)) by Stanley
B. Prusiner to distinguish the infectious pathogen that causes TSEs from viruses and viroids.
Naturally, all infectious agents are proteinaceous to some degree. What sets prions apart, as
proposed by Prusiner, is that the actual infectious principle consists merely of protein and is
1Aggregates of amyloid-β (Aβ) peptide associated with Alzheimers disease behave like an
infectious agent when injected into the brain of a mouse model of Alzheimers disease, showing
a pattern of Aβ deposition that depends on both the host and the agent (168). These findings
suggest that what was considered to be a unique feature of prion disease may be a more general
property of amyloids
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capable of replicating and transmitting infections without the need for informational nucleic
acids (147; 197).
The protein-only hypothesis 1 states that the agent responsible for the propagation of prion
diseases is not a virus but a post-translationally modified form of the cellular prion protein,
PrPC (C=Cellular) 2 denoted as PrPSc (Sc=Scrapie). Prusiner and co-workers proposed that
PrPSc is the main or only constituent of the prion. Because the sequence of PrPC is the same
as that of PrPSc, the two species are believed to differ in their conformation (218).
Furthermore, the protein only hypothesis states that, when introduced in a normal host,
PrPSc induces the conversion of PrPC into PrPSc, and that this conversion is the main
event in the propagation of prion diseases. Although still controversial (42), the notion that
transmissible spongiform encephalopathies can be propagated by a mechanism involving self-
perpetuating changes in protein conformation is supported by a wealth of infection studies
(59; 199; 243).
3.2 Toxicity
PrPC needs to be presented by host neurons for neurodegeneration to occur (4).
Consistently, mice lacking the prion gene are resistant to the disease (37). Indeed, when neu-
rografts propagating PrPSc were implanted into Prnp knockout mice, no pathological changes
were seen in PrP-deficient tissue, even in the immediate vicinity of the grafts (32).
Even if the formation of PrPSc accompanies neurodegeneration in prion disease, many lines
of evidence indicate that PrPSc is not intrinsically neurotoxic (4).
The importance of neuronal expression of PrPC for prion disease development has been
corroborated also by the phenotype of mice with neuron-specific ablation of PrPC eight weeks
1First outlined in general terms by Griffith (96) and enunciated in its updated and detailed
form by Prusiner (200)
2PrPC is synthesized in the endoplasmatic reticulum, processed in the Golgi apparatus and
then carried, in its mature form, to the cell surface (199). PrPC is classified as GPI-anchored
plasma-membrane glycoprotein (22; 49; 183) and it is found predominantly on the outer surface
of neuronal and glial cells. Its physiological function is still unclear; Glycosylphosphatidylinos-
itol (GPI anchor) is a glycolipid that can be attached to the C-terminus of a protein during
post-translational modification. It is composed of a phosphatidylinositol group linked through
a carbohydrate-containing linker to the C-terminal amino acid of a mature protein. The two
fatty acids within the hydrophobic phosphatidylinositol group anchor the protein to the cell
membrane. Glypiated (GPI-linked) proteins contain a signal peptide, thus directing them into
the endoplasmic reticulum (ER). The C-terminus is composed of hydrophobic amino acids that
stay inserted in the ER membrane. The hydrophobic end is then cleaved off and replaced by
the GPI-anchor. As the protein processes through the secretory pathway, it is transferred via
vesicles to the Golgi apparatus and finally to the extracellular space where it remains attached
to the exterior leaflet of the cell membrane. Since the glypiation is the sole means of attach-
ment of such proteins to the membrane, cleavage of the group by phospholipases will result in
controlled release of the protein from the membrane
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after prion inoculation. Early spongiform changes were reversed, and clinical disease was pre-
vented. This reversal occurred despite the accumulation of extraneuronal PrPSc (157).
Membrane attachment of PrPC is a prerequisite to initiate neurodegeneration and that the
presence of PrPSc alone does not cause disease (4).
Consistently, transgenic mice expressing only a secreted form of PrPC , lacking its mem-
brane attachment via GPI anchor, have been reported to be refractory to develop clinical signs
of prion diseases, although prion inoculation induces PrPSc formation and aggregation of amy-
loid plaques (50).
3.3 Structural and Physical Properties
The two PrP isoforms have remarkably different biophysical properties.
PrPC is readily degradable by proteinase K, while PrPSc is only partially degraded upon
proteolytic digestion (162; 183). PrPC is an α-helical, soluble monomeric protein, whereas
PrPSc has a βsheet rich structure and forms large aggregates which are insoluble in non-
denaturing detergents and often appear as amyloid fibrils (167; 184; 187).
Human PrPC is a 209 residues protein 3.1, consisting of a largely unordered N-terminal
region (residues 23-124) and a folded C-terminal domain (residues 125-231) (247). The protein is
highly conserved across mammals (187; 203), indeed its NMR structures expressed by different
mammals are similar (54; 55; 92; 153; 247).
The C-terminal globular domain is from residue 125 to 228 in the human numbering.
It contains three α-helices comprising the residues 144-154, 173-194 and 200-228 and a very
short anti-parallel β-sheets comprising residues 128-131 and 161-164. A single disulfide bond,
Cys179-Cys214, connects helices 2 and 3. NMR studies have revealed that the structure of
the C-terminal domain is preserved even in the absence of the N-terminal part of the protein
(187; 203; 247). The N-terminal region contains characteristic glycine-rich octapeptide repeats
(PHGGGWGQ human sequence) which enables the protein to coordinate Cu(II) ions (169; 235).
It is unlikely that the N-terminus is randomly coiled also in vivo, since functional studies in
transgenic mice imply that the domain comprising amino acids 32-121 carries out important
physiological functions (212). The flexible tail of PrPC might acquire a defined structure when
PrPC is present within membrane rafts (172).
The transition between human PrPC and PrPSc, proposed within the protein only hy-
pothesis, occurs post translationally without any detectable covalent modifications (218). The
molecular basis of the PrPC → PrPSc conversion is currently far from being clear and several
models have been proposed (see Appendix B). The earliest event in the conversion involves the
formation of a stable intermediate (112; 249), which has not been characterized yet. Never-
theless, the existence of such partially structured monomeric folding intermediate of the prion
protein is also indicated by hydrogen-deuterium exchange (139) and high-pressure spectroscopy
experiments (176).
PrPSc is believed to aggregate on a smaller scale and then progress into protofibrils before
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Figure 3.1: The Human Prion Protein - The mature human prion protein.
It features two signal peptides (1-23 and 231-235), an octapeptide repeat region
(involved in binding Cu2+ ions (169)), three α-helixes, one disulphide bond (SS)
between cysteine residues 179 and 214, and two potential sites for N-linked gly-
cosylation (green forks) at residues 181 and 197. A glycosylphosphatidylinositol
anchor (GPI) (yellow box) is attached to the C-terminus of PrP.
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forming ordered rigid fibrils (5). No atomic-resolution information of any of these structures
have been obtained so far (5; 7), due to the insoluble nature of the aggregates (173; 214; 219).
Fourier-transform infrared (187) and CD spectroscopy (207) reveal a higher β-sheet content
of PrPSc respect PrPC . Moreover, the discovery of 2D crystals of PrPSc and of a fibril-
logenic miniprion, PrPSc (with residues 141176 deleted)(244), provided additional structural
constraints for modeling PrPSc (244). According to this, different model describing the mam-
malian prion structure have been suggested that can be clustered in two groups whose repre-
sentative structures are: the spiral model (72) and the β-helix model (93).
Figure 3.2: Scrapie Models - A) the spiral model (72) and B) the β-helix model
(93) on the basis of EM image of the two-dimensional protofibril by Wille et al.
(244)(C)
To systematically evaluate the relationship between infectivity, converting activity, and
the size of various PrPSc-containing aggregates, Caughey and co-workers (213) partially dis-
aggregated PrPSc aggegates. The resulting species were fractionated by size. Intracerebral
inoculation of the different fractions into hamsters revealed that nonfibrillar particles, with
masses equivalent to 1428 PrP molecules, are the most efficient initiators of TSE disease (213).
Thus, as with other diseases characterized by protein aggregation, such as Alzheimers dis-
ease and Parkinsons (16), the formation of large amyloid fibrils might be a protective process
that sequesters the more dangerous subfibrillar oligomers of the amyloidogenic peptide or pro-
tein into relatively innocuous deposits (43; 126). Fibrils in TSEs, known as prion rods, are
composed of PrP 2730, a fragment of PrPSc resulting from proteinase K digestion of the first
∼ 88 residues. Prion rods possess the tinctorial properties of amyloid fibers (162; 198) and
resemble amyloid fibrils found in vivo (70).
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3.4 Pathogenic Mutations
3.4.1 Disease-linked Mutations accelerate PrPC to PrP Sc
conversion
One of the key arguments in support of the protein-only hypothesis is the evidence linking
familial prion diseases (about 15% of human prion diseases (135; 164)) with mutations in the
gene coding for human prion protein (59; 199; 243).
Indeed in individuals carrying these mutations the conversion of PrPC to PrPSc appears
to develop spontaneously (223).
Hence, the primary role of these mutations might be increase the likelihood of misfolding
by the thermodynamic destabilization of PrPC (150; 223) in favor of a folding intermediate
that is likely to be a PrPSc precursor (13; 220). Kinetic studies using both stopped-flow and
continuous-flow methods indicate that a number of PrP variants carrying mutations correspond-
ing to inherited prion diseases results in a destabilizing effect of the PrPC conformer toward
a pronounced stabilization and thus increased population of the folding intermediate. For each
mutant protein tested, the population of an intermediate was found to be at least 1 order of
magnitude higher than that of the fully unfolded state (220). This effect was observed even for
mutations with only a minor effect on the global stability of the native state of prion protein
(12; 13).
3.4.2 Pathology
Despite the rarity of PRNP mutations, the protracted clinical course of some inherited prion
diseases leads to a high population prevalence relative to sporadic and acquired prion diseases
(164).
Over 30 different mutations have been described: some are typically associated with par-
ticular clinical categories of prion disease; others are associated with a spectrum of clinical
phenotypes, often with striking phenotypic variability (164) (238).
Historically, variation in clinical phenotype of inherited prion diseases has been encapsulated
by three clinical categories: GSS (Gerstmann, 1936, reviewed by (102)), FFI (155), and familial
Creutzfeldt-Jakob disease (fCJD) (Jakob, 1923, described by (34)). The clinical categories of
inherited prion diseases may be seen as extremes of phenotype, in reality the syndromes overlap
considerably (164).
The existence of phenotypic overlap between individuals with different mutations and even
in family members with the same PRNP mutation indicates that accurate classification of
inherited human prion diseases should be based upon mutation alone (135).
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Rev 8/1/2010 
National Prion Disease Pathology Surveillance Center 
Cases Examined1      
(July 31, 2010) 
1 Listed based on the year of death or, if not available, on year of referral; 2 Cases with suspected prion disease for which brain tissue and/or blood (in 
familial cases) were submitted; 3 Disease acquired in the United Kingdom; 4 Disease was acquired in the United Kingdom in one case and in Saudi Arabia 
in the other case; 5 Includes 16 cases in which the diagnosis is pending, and 18 inconclusive cases; 6 Includes 21 (19 from 2010) cases with type 
determination pending in which the diagnosis of vCJD has been excluded.  
Year Total Referrals2 
Prion 
Disease Sporadic Familial Iatrogenic vCJD 
1996 & earlier 51 33 28 5 0 0 
1997 114 68 59 9 0 0 
1998 88 52 44 7 1 0 
1999 120 72 64 8 0 0 
2000 146 103 89 14 0 0 
2001 209 119 109 10 0 0 
2002 248 149 125 22 2 0 
2003 274 176 137 39 0 0 
2004 325 186 164 21 0 13
2005 344 194 157 36 1 0 
2006 383 197 166 29 0 24
2007 377 214 187 27 0 0 
2008 394 231 204 25 0 0 
2009 425 259 216 43 0 0 
2010 204 124 85 20 0 0 
TOTAL 37025 21776 1834 315 4 3 
Figure 3.3: Case of TSEs - Case of TSEs examined Until July 31,
2010 available on the National Prion Disease Pathology Surveillance Centre
(http://www.cjdsurveillance.com/ ) Division of Neuropathology of Case Western
Reserve University)
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Figure 3.4: Mutations - (revisited from (4)) The human PrPC protein and its
mutants. The mature human PrPC protein contains 209 amino acid residues. It
features two positively charged amino acid clusters denoted CC1 and CC2 (blue
boxes), an octapeptide repeat region (OR) (green boxes), a hydrophobic core (HC)
(gray box), three α-helixes (H1-H3) (red boxes), one disulphide bond (SS) between
cysteine residues 179 and 214, and two potential sites for N-linked glycosylation
(red forks) at residues 181 and 197. A glycosylphosphatidylinositol anchor (GPI)
(yellow box) is attached to the C-terminus of PrP.
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3.4.3 Location of the mutated residues in PrPC structure
A key question for pharmacological intervention against pathogenic variants is how the iden-
tified mutations in PRPN gene affect the conversion of PrPC to PrPSc and aggregation. In
particular, structural studies on PrP variants containing familial mutations might provide im-
portant clues regarding the molecular basis of the disease. On the basis of their occurrence
in the sequence, the reported pathogenic mutations can be classified in three different groups
(230) 1:
- Mutations in the flexible N-terminal region
- Mutations in the globular domain 2
- Mutations in the GPI-signal peptide
Mutations in the flexible N-terminal region
It is likely that the flexible N-terminus is involved in the conversion from PrPC to PrPSc (71).
In particular, residues from 112 to119 are required for the formation and propagation of PrPSc
(179). The importance of the flexible N-terminus in causing disease is supported also by the
existence of a short neurotoxic peptide (residues 106-126), which has a high intrinsic ability to
polymerize into amyloid-like fibrils in vitro (34; 83).
There are four residues linked to GSS causing mutations in the flexible N-terminus of
human PrP: P102L, P105L/S/T, G114V and A117V. However, there is little evidence for a
direct molecular effect of these mutations in the flexible N-terminus on the globular structure
of PrPC or conversion to PrPSc, also because most of the available studies on these mutants
have focused on small fragments of the PrP protein (230). It is possible that β-sheet formation
in the N-terminal region is enhanced, but it could also be that the disease-causing ability of
these mutants arises due to more complex interactions at the cellular level (230). Jones et al.
(120) compared the fibril formation of the 23 144 fragment with the mutations P102L, P105L
and A117V to the WT. No significant effects on the amyloidogenicity were found, confirming
the results obtained by neurotoxicity studies with small peptides (34; 83).
Mutations in the globular domain
Because of structural information of this domain is available (247), here we are able to discuss
the type of interactions the mutated residues form in the protein. On the basis of the type of
amino acid replacements involved we can divide mutations in (230):
- Stop Mutations
- Mutations affecting salt-bridge interactions in the globular domain
- Mutations of polar residues in the globular domain
1Insertions or deletions in the octarepeat region of the PRPN gene have also been linked to
prion disease in humans (24; 91) but they will be not discussed here.
2For a number of mutations (S132I, A133V, T193I, E196K), no information is available
apart from their occurrence in cases of inherited spongiform encephalopathies.
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- Hydrophobic mutations in the globular domain
Stop Mutations. Two stop mutations have been observed in patients that result in a
truncated version of PrP: Y145stop and Q160stop, located in α1 and β2 respectively. Further
research has mostly been performed on the Y145stop mutant. The largely missing C-terminal
globular domain in this mutant is normally required to import the complete PrP into the
Endoplasmatic Reticulum (105). Without this happening, a large portion of the truncated
PrP is not post-translationally processed (keeping its N-terminal signal peptide) and rapid
degradation by the proteasome occurs (77; 248). It was found that a recombinant fragment
containing residues 23-144 can convert spontaneously to a fibrillar form, with residues 138-141
being essential for its formation (137).
Mutations affecting salt-bridge interactions in the globular domain. Salt bridges
are often involved in stabilization of the tertiary structure of a protein. Six known disease-
causing mutations can directly affect salt-bridge interactions in the globular PrP domain:
R148H, D178N, E196K, E200K, R208H and E211Q.
R148 is located in helix 1 and can form salt bridges with D144 and E146, thereby his
substitution could alter the pattern of salt bridges along helix α1. This network of interactions
was shown to confer stability of α1, both experimentally (166; 217) and theoretically (74; 208).
Apart from the similarity of R148H PrPSc aggregates to those observed in a sporadic form of
CJD (189), no information on the effect of this mutation is available. The same is for E211Q
and E196K.
The D178N mutant, located in helix 2, is probably the most extensively studied PrP mu-
tation and is involved in a large number of disease cases (164). Intriguingly, the mutation
causes FFI in combination with M129 and fCJD in combination with V129 (90), although this
distinction may not be so clear-cut (163). D178 residues is involved in the salt bridge with
R164 (located on β2) and can also be involved in hydrogen bond interactions with the Y128
and Y169 side chains (located at the beginning of strand β1 and the loop between β2 and α2,
respectively). Protonation of D178 in MD studies leads to the loss of these interactions, which
may facilitate conversion (8). This hydrogen bond is also lost in most of the mutant we studied
allowing a more flexibility of the loop and a major exposure of the Y169 toward the surface of
the protein.
E200K is the major causative mutation related to fCJD (164), and its phenotype is influ-
enced by the M/V129 polymorphism (201). E200 is located at the beginning of helix 3, thus
it was argued that the mutation may affect the stability of helix α3 (86). Either if it does not
seem to significantly affect the overall thermodynamic stability of PrPC (223), however this
mutations change the surface electrostatic potential of the protein (252) causing abnormalities
in interactions of PrP with other proteins in the cell or the cell membrane itself (209).
For R208, the situation is less clear; Zuegg and Gready (1999) (253) argued that a salt
bridge between E146 and R208 could stabilize the tertiary structure of PrPC and its loss may
facilitate conversion to PrPSc. MD simulations of WT PrP (residues 125 -228), R208H PrP
and WT PrP with neutralized D144 and E146 (to break the putative salt-bridge interaction),
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however, showed no significant rearrangements upon breaking the interaction, whereas the
introduction of the R208H mutation did (19).
Mutations of polar residues in the globular domain. Three of the polar residue
mutations are found in helix 2: T183A, H187R, T188R/K/A.
Mutation of T183 to A disrupts hydrogen bond interaction between the T183 side chain
and the backbone nitrogen of Y162, which can help to anchor the native sheet to the core of α2
and α3, preserving the stability of the folds . This mutant indeed affects both in vivo folding
and GPI-anchor attachment (? ) and can cause abnormal glycosylation (95). Accordingly,
mouse T183A PrP 121 231 expressed in E. coli aggregates and shows a significantly decreased
stability compared with WT (150).
The H187R mutation may disrupt a putative interaction between helix 2 and helix 3 (142).
It has been related to both fCJD (98) and GSS disease with abnormal PrPSc deposits (63)
since H187R PrP accumulates in lysosomes instead of moving to the cell surface (98).
Directly adjacent to H187 is T188, which can mutate to R, K or A, causing fCJD. These
mutant PrPs show an increased proteinase K resistance and detergent insolubility that can be
indicative of a (higher) degree of aggregation (230).
Three other pathogenic mutations of polar residues are located in helix 3: D202N, Q212P,
Q217R.
The first is D202, which forms a (conserved) stabilizing capping box with T199 at the top
of the helix (204). Combined CD and NMR study of peptides corresponding to helix 3 showed
that the D202N mutation completely destabilizes its structure (86). Accordingly, in a human
cell model, D202N PrP accumulates and aggregates in the Endoplasmatic Reticulum without
reaching a mature conformation (99).
The mutation of Q212P is remarkable as it inserts a proline in the middle of helix 3, which
affects its structure (115). The only effect of this mutation currently known is that Q212P PrP
accumulates and eventually forms aggresomes in the cytosol upon proteasomal inhibition (170).
The final mutation in helix 3 is Q217R. It lacks a GPI-anchor, which probably causes
the observed impaired transport to the cell surface, and it exhibits increased aggregation and
proteinase resistance (215). Most of these alterations are temperature-sensitive, indicating that
they are due to misfolding of PrP (215). Indeed MD simulation studies have shown that Q212
is involved in a tight hydration site: a water molecule can bind between the backbone carbonyl
of S132 (in β1), the backbone amide of V161 (in β2) and the side chain oxygen of Q217 (69).
When Q217 is mutated in R, the large side chain of the arginine replaced the tightly bound
water and forced other rearrangements, which may facilitate fibril formation (69).
Hydrophobic mutations in the globular domain. The remaining pathogenic muta-
tions in the globular domain of PrP affect hydrophobic residues. V180I, F198S and V210I have
been indicated to cause atypical glycosylation, to interference with GPI-anchor attachment (46?
) and to affect the folding pathway of PrP (13). Further studies on F198S mutation reveal that
it leaves a gap in the hydrophobic core (204) and as expected, the thermodynamic stability of
PrPC is significantly affected as in vitro (150) and in silico (251).
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Mutations in the GPI-signal peptide
There are three mutations in the GPI-signal peptide associated with fCJD: M232R, M232T
and P238S (230).
The mechanism of cytotoxicity of these mutants remains unknown as the signal peptide is
cleaved off within 5 min of PrP synthesis and translocation into the Endoplasmatic Reticulum
(152). Recently, Gu et al. (2008) (97) showed that M232R and M232T do not interfere with
GPI-anchor addition, but do cause PrP being bound to the membrane in an alternative (C-
transmembrane) orientation (15).
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4Structural facets of disease-linked
human prion protein mutants: a
molecular dynamic study
Prion propagation in transmissible spongiform encephalopathies involves the con-
version of the cellular prion protein (PrP), PrPC , into the pathogenic conformer
PrPSc. Human familial forms of the disease are linked to specific mutations in the
PrP gene, PRNP, and include Gerstmann-Strussler-Scheinker syndrome (GSS), famil-
ial Creutzfeldt-Jakob disease (fCJD) and Fatal Familial Insomnia. To gain insights
into the molecular basis of these disorders, we performed classical molecular dynamic
simulations in aqueous solution on wild type (WT) human PrP (HuPrP), and on three
HuPrP variants located in the globular HuPrP domain: two pathological mutations,
HuPrP(Q212P) and HuPrP(E200K), linked to GSS and to fCJD respectively, and
one protective polymorphism, HuPrP(E219K). A comparison between the predicted
structural determinants of WT HuPrP and one of its mutant (HuPrP(E200K)) with
the available structures established the accuracy of the methods used. Strikingly,
the analyzed disease-linked variants had their major effect on the α2-α3 region and
the β2-α2 loop, regardless of the mutation position. The conformational change of
the latter might affect the interactions with cellular partners in the fibrillation pro-
cess. The protocol proposed here represents a powerful approach for reproducing the
structural effects of genetic mutations located in the globular domain of HuPrP.
4.1 Introduction: pathogenic mutations of hu-
man prion protein
There are more then twenty mutations of the prion protein gene that are know to be asso-
ciated with human TSE (230). The purpose of our work is identifying common structural
features among these mutants in order to shed light on the molecular basis of prion diseases.
Experimental studies suggested that α2-α3 region constitute the main seeding element for the
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conformational transition and the fibrillogenesis of the PrP. These include: (i) high-pressure
NMR hydrogen/deuterion exchange studies (138; 139; 154). (ii) Isotope exchange experiments,
which point to relatively large conformational flexibility of the region (247). (iii) Recent NMR
studies (2), which proved that the isolated α2-α3 region is highly fibrillogenic and forms amy-
loid fibres morphologically similar to those obtained for the full-length protein. Consistently, in
silico studies point to a relatively low helical propensity of the region (73? ). Interestingly, most
point mutations linked to inherited prion diseases (199) are clustered in this region (135; 202)
and cause spontaneous conversion (223). The primary role of these mutations might increase
the likelihood of misfolding by the thermodynamic destabilization of PrPC (150; 223) in favor
of a folding intermediate (13) that is likely to be a PrPSc precursor (12; 14). Considering this,
structural studies with PrP variants containing familial mutations may provide clues regard-
ing the proposed mechanism and may also shed lights on the role of the α2-α3 region that is
proposed to be involved in the early stage of the conversion (2; 138; 139).
Here, we report molecular dynamics (MD) simulationbased structural predictions starting
from the globular domain of the WT HuPrP deposited structure (38; 247), able to predict
structural facets in aqueous solution of pathological mutations located in the globular domain
of HuPrP. Interestingly, our calculations uncover common structural features specific for the
pathogenic mutants, not present in the WT HuPrP. These features involve the same regions
of HuPrP, although the mutations considered are different for position and characteristics. In
particular, the conformational flexibility of the β2-α2 loop (residues 165-172) and of the α2-α3
region (residues 180-205) increase. The latter finding is fully consistent with the proposed role
of α2 and α3 helices for the conversion (2; 138; 139; 154). For building up our computational
protocol we chose to consider only homozygote mutants with high percentage of incidence (more
than 1.1%) and carrying the methionine polymorphism 1 at codon-129 (129M). We chose 129M
since WT HuPrP with the V129 polymorph displayed an increased lag phase compared with
129M (149). This means that the 129M version formed fibrils readily. In stark contrast, 129V
did not form amyloid, even after more incubation time at twice the protein concentration respect
the M version (149). Thus the systems chosen are two pathological mutations, HuPrP(E200K)
(252) and HuPrP(Q212P) (193) causing familial CJD and GSS, respectively (202), and of the
protective mutant HuPrP(E219K) (210; 211), also classified as protective polymorphism.
4.2 Computational Setup
We considered four prion systems in our study: the WT HuPrP (125-228), two pathogenic mu-
tants, HuPrP(E200K) and HuPrP(Q212P), and the protective polymorphism HuPrP(E219K).
1Polymorphism in biology occurs when two or more clearly different phenotypes exist in
the same population of a species, more in detail, a polymorphis is a allelic variants that change
the population with a frequence more than 1%. The human prion protein has a common
polymorphism at residue 129, which can be valine or methionine. The polymorphic variation
has a profound influence on the ability of the protein to form amyloid fibrils spontaneously
(149) (see Appendix A ).
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For the WT HuPrP we used the coordinates of the deposited NMR structure of HuPrP at pH 7
(PDB code: 1HJN (38; 247), residues 125-228, in Figure 4.1) carrying the methionine polymor-
phism at codon-129. The disease-causing HuPrP mutants HuPrP(E200K) and HuPrP(Q212P),
and the polymorphic HuPrP(E219K) structures were obtained inserting the mutation on the
NMR WT HuPrP via the Swiss-Pdb viewer package (100). Also for these mutants we main-
tained the same methionine polymorphism at codon-129. The four systems were simulated in
explicit aqueous solution, inserted into a cubic box (box vector 7.18 nm) of water molecules,
ensuring that the solvent shell would extend for at least 1.6 nm around them. Thus, the number
of water molecules varied from a minimum of 9251 in the HuPrP(Q212P) system to a maxi-
mum of 9345 in the HuPrP(E200K) system. The AMBER99 force field (41; 242) was used for
the protein, in combination with the AMBER-adapted Aqvist potential for the counter ions,
(1) and the TIP3P force field for the water (122). Neutral pH conditions were realized by
setting the protonation states of the ionizable residues according to their pKas. In particular
the counter ions used here are the Na+ ions. Simulations were performed in periodic boundary
conditions in the NPT ensemble, with temperatures and pressure kept close to the desired value
(T = 298 K, P = 1 bar) through the Nos-Hoover (110; 180) and Andersen-Parrinello-Rahman
(181; 188) coupling schemes respectively. Long-range electrostatic interactions were treated
with the particle mesh Ewald (PME) (66; 80) method, using a grid with a spacing of 0.12 nm,
combined with a fourth-order cubic spline interpolation (107) to compute the potential and
forces in between grid points. The cutoff radius for the Lennard-Jones interactions, as well as
for the real part of PME calculations, was set to 0.9 nm. The LINCS algorithm (106) was used
to constrain all bond lengths involving hydrogen atoms and the time-step used was 2 fs. The
systems were energy-minimized imposing harmonic position restraints of 1000 kJmol1nm2 on
solute atoms, allowing the equilibration of the solvent without distorting the solute structure.
After an energy minimization of the solvent and the solute without harmonic restraints, the
temperature was gradually increased from 0 to 298 K. This was performed in 12 steps, in which
the temperature was increased by 25 K in 100 ps of MD. Each system was finally simulated for
50 ns. Four simulations were carried out for each system: the same models were used; however,
we assigned statistically independent initial velocities harvested from a Maxwell distribution
at the appropriate temperature. This allows generating four sets of statistically independent
trajectories sampling the same Boltzmann distribution. All simulations were performed and
analyzed with the GROMACS software package (27). g sas was used for computing the solvent
accessible surface area with a probe radius of 0.14 nm. g mdmat was used to make distance
matrix in function of time consisting of the smallest distance between residues pairs. A distance
cutoff of 0.5 nm was used as a discrimination criterion for the presence of both salt-bridge (SB)
and pi-stacking interactions. For the SB interaction, we used the distance from the anionic car-
boxylate (RCOO-) of either aspartic acid or glutamic acid and the cationic ammonium (RNH+3 )
from lysine or the guanidinium (RNHC(NH2)2+) of arginine. For pi-stacking interactions, we
used the center of mass of atoms belonging to the aromatic ring as the representative point
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for the distance criteria 1 The H-bonds were determined based on a cutoff distance of 0.35 nm
between Hydrogen and Acceptor and a cutoff angle of 30 degree on Acceptor-Donor-Hydrogen
angle.
Clusterization on MD trajectories.
The module g cluster was used for clusterizing the trajectory by the gromos method (67) and
a RMSD cutoff of 0.1 nm; We followed two different approaches to cluster the MD trajectories:
(i) Partial clusterization. We focused here on each single trajectory for each system. The
results turn out to be very similar among the trajectories. This strengthens the accuracy of our
computational protocol.
(ii) Total clusterization. We focused here on the global set of trajectories for each system.
As expected, the results turn out to be very similar to those of (i). The total clusterization is
reported in Appendix C.
4.3 Results
Here we perform 50 ns MD simulations for WT HuPrP structure (in our notation MD WT),
HuPrP(E200K) (MD E200K herafter), HuPrP(Q212P) and HuPrP(E219K). The statistical ac-
curacy of our result was investigated by performing four independent simulations for each
system. The resulting findings are very similar for each set of four runs. We first established
our setup by comparing MD WT with the corresponding NMR deposited structure (PDB code
1HJN (38; 247), in Figure 4.1 A and in our notation NMR WT). Next, we compare MD E200K
(Fig.4.1) with the NMR structure (PDB code: 1FO7 (252), in our notation NMR E200K). The
variant is constructed by an in silico mutation of NMR WT (see Methods). The calculations
allow to establish the predictive power of this procedure (Comparison is also made with the
recently solved X-ray structures of WT HuPrPs 2 and its mutants (145), albeit our work fo-
cuses on the structure of the protein in water solution). Hence, we used the same in silico
mutation setup for predicting the structures of HuPrP(Q212P) and HuPrP(E219K), in Fig.
4.1 B. We focus on the regions for which we observed a larger conformational flexibility in the
mutants relative to WT HuPrP. These are the α2-α3 region (residues 180-205) and the β2-α2
loop (residues 160-175).
4.3.1 WT HuPrP.
The fold of the protein, as obtained by MD calculations, was the same as that of NMR WT.
For the backbone root main square deviation (RMSD) differences between MD WT HuPrP
1The respective orientation of the aromatic rings and thus the type of pi-stacking interactions
have not been investigated here.
2Notice that for this comparison we considered only the monomeric form, as our simulations
provided the structural determinants for the monomer in solution
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Figure 4.1: Models studied - A) NMR structure of the globular domain of WT
HuPrP (PDB code 1HJN(38; 247) and in our notation NMR WT). The view on
the right highlights the only S-S bridge present in the structure. B) The HuPrP
mutants MD E200K, MD Q212P and MD E219K, as emerging from the MD simu-
lations. The color-coding of the systems is the same in all the figures (i.e. Black for
the MD WT, red for MD E200K, green for MD Q212P and blue for MD E219K).
The snapshots reported here correspond to the most populated cluster. The mu-
tated residue is indicated in ball-and-sticks.
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and NMR WT were smaller than 0.12±0.01 nm for the entire folded domains and less than
0.09±0.01 nm for the non-loop; this was found for all the four simulation performed on the WT
(see Tab. 4.2).
Reference: NMR 
corresponding structure (nm)* 
 
 
Reference: MD_WT 
structure (nm) 
Folded-domain Non-loop 
MD_WT 0.14±0.05  0.11±0.01 0.09±0.01 
MD_WT 1 0.14±0.05 0.11±0.01 0.09±0.01 
MD_WT 2 0.12±0.03 0.12±0.03 0.09±0.01 
MD_WT 3 0.12±0.03 0.12±0.03 0.09±0.01 
MD_E200K 0.20±0.02 0.20±0.02 0.15±0.01 
MD_E200K 1 0.13±0.02 0.13±0.02 0.09±0.02 
MD_E200K 2 0.13±0.03 0.13±0.02 0.09±0.02 
MD_E200K 3 0.14±0.03 0.14±0.02 0.09±0.01 
MD_Q212P 0.17±0.02 Not available 
MD_Q212P 1 0.14±0.02 Not available 
MD_Q212P 2 0.15±0.02 Not available 
MD_Q212P 3 0.15±0.02 Not available 
MD_E219K 0.20±0.03 Not available 
MD_E219K 1 0.13±0.02 Not available 
MD_E219K 2 0.12±0.0.2 Not available 
MD_E219K 3 0.12±0.0.2 Not available !
Figure 4.2: RMSD table - Partial clusterization. RMSD values of the system
studied respect the MD WT structure. The structure chosen as the reference is
the representative structure of the most populated cluster coming from our cluster
analysis.
The most flexible regions are the β2-α2 loop and the α2-α3 region, as obtained by the plot
of the root mean square fluctuation (RMSF) (Fig. 4.3).
The α2-α3 region.
Several specific salt bridges (SBs) and hydrophobic long-range interactions in the helical inter-
face have been proposed to play a fundamental role in fold stabilization of α2-α3 region (Fig.
4.6 A)(2). Their importance is supported by the observation that some of them are absent in
a number of disease cases (Fig. 4.6 B) (2).
The charged residues involved in SBs, five in helix 3 (Glu200, Lys204, Glu207, Arg208 and
Glu211) and one in helix 2 (Glu146) formed a well-packed electrostatic net. Specifically, four SBs
were present (Fig. 4.6 A and 4.4 ): two of these were formed by Arg208 with both Glu207and
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Figure 4.3: Root mean square fluctuations (RMSF) - RMSF of the MD
structures as a function of residue number. The regions that showed higher flex-
ibility are highlighted. The first and the last residues have a RMSF value higher
than 0.3 nm, since they are in a terminal position. Thus they are omitted here.
Notably each point is a mean value calculated on all the simulations for the same
system.
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Systems MD_WT 1 MD_WT 2 MD_WT 3 MD_WT 4 
Total population collected 
(%) 80 81 80 80 
Relative population 
collected (%) 61.2 21.7 17.1 72.4 13.9 13.7 62.3 20.7 17.0 59.7 23.5 16.8 
Cluster 1 2 3 1 2 3 1 2 3 1* 2 3 
Arg208 -Glu211 0.39 0.40 0.38 0.40 0.40 0.41 0.41 0.40 0.39 1.02 0.48 0.38 
Glu207-Arg208 0.39 0.44 0.45 0.40 0.39 0.39 0.37 0.43 0.44 0.82 0.45 0.43 
Lys204-Glu207 1.01 0.97 1.05 0.99 0.99 0.96 0.98 0.93 1.04 0.35 0.84 0.99 
Glu200/Lys200-
Lys204 0.93 0.37 0.92 0.38 0.92 0.76 0.89 0.47 0.82 0.99 1.28 0.48 
SB
(n
m
) 
Glu146-Lys204 0.78 0.84 0.35 0.89 0.49 0.76 0.77 0.84 0.38 0.99 0.40 0.99 
Figure 4.4: MD WT SBs - Lys204-Glu200, Lys204-Glu146, Lys204-Glu207,
Arg208-Glu207 and Arg208-Glu211 SBs.The distances are calculated in the first three
clusters (able to collect more or less the 80 per cent of the total population) com-
ing from a clustering analysis on the overall trajectory for three independent MD
simulations for each system.
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Glu211 (Block A); the other two were formed by Lys204 with Glu200 and Glu146 (Block B).
In Block A, Arg208 position remained fixed overall the simulation by an hydrogen bond with
Gln212; as a consequence, Arg208-Glu207 and Arg208-Glu211 SBs remained stable overall the
simulation. In Block B, Lys204-Glu200 and Lys204-Glu146 were instead alternatively formed and
broken: Lys204 side chain switched indeed from a conformation closed to Glu200 to another
closed to Glu146. From the cluster analysis of the MD trajectory, we found that, in the most
populated cluster Lys204 was in a middle position between both. In the second most populated
cluster, Lys204 was close to Glu200 while in the third cluster, Lys204 was close to Glu146 (Tab.
4.4 ). A similar result was found in the 20 conformers reported for NMR WT. In nine clusters
Lys204 was in a middle position, in seven clusters, Lys204 was close to Glu200, and in the
other four Lys204 was close to Glu146. Hence, our computational setup reproduces this key
feature of the NMR structure. In one of the other three MD simulations we observe a different
conformation for the SB interactions in one of the cluster: Glu146 interacts with Arg208 instead
of Lys204. This forms a SB not observed in all the other simulations (see 4.4).
We next focus on another key feature of the region. This is the disulphide bond between
Cys179 and Cys214 (Fig. 4.1, right), since disulphide bridges are well known to play key roles in
stability, folding and functions of proteins. The structure of a disulfide bond can be described
by its χSS dihedral angle between the Cβ Sγ Sγ Cβ atoms, which is usually close to ± 90
degrees. Here, χSS was ∼ -90 degrees.
Interaction !-stacking (Cys
179-Cys214) 
bridge 
Systems Tyr169-Phe175 (nm) Phe175 - Tyr218 (nm) C"- C"(nm) 
MD_WT 1 0.45±0.02 0.46±0.03 0.68±0.01 
MD_WT 2 0.44±0.02 0.45±0.02 0.68±0.01 
MD_WT 3 0.45±0.02 0.46±0.03 0.69±0.01 
MD_WT 4 0.45±0.02 0.46±0.02 0.68±0.01 !
Interaction !-stacking (Cys
179-Cys214)  
bridge 
Systems Tyr169-Phe175 (nm) Phe175 - Tyr218 (nm) C"- C"(nm) 
MD_E200K 1 0.84±0.07 0.50±0.04 0.65±0.02 
MD_E200K 2 0.72±0.09 0.47±0.03 0.65 ± 0.02 
MD_E200K 3 1.12±0.10 0.46±0.03 0.65±0.02 
MD_E200K 4 0.80±0.15 0.47±0.03 0.65±0.02 !
Interaction !-stacking (Cys
179-Cys214) 
bridge 
Systems Tyr169-Phe175 (nm) Phe175 - Tyr218 (nm) C"- C"(nm) 
MD_Q212P 1 0.86±0.05 0.47±0.03 0.65±0.02 
MD_Q212P 2 0.93±0.18 0.46±0.02 0.65±0.02 
MD_Q212P 3 0.80±0.18 0.46±0.02 0.65±0.01 
MD_Q212P 4 0.90±0.22 0.48±0.04 0.66±0.02 !
Interaction !-stacking (Cys
179-Cys214) 
bridge 
Systems Tyr169-Phe175 (nm) Phe175 - Tyr218 (nm) C"- C"(nm) 
MD_E219K 1 0.44±0.04 0.43±0.02 0.67±0.01 
MD_E219K 2 0.44±0.02 0.46±0.02 0.68±0.01 
MD_E219K 3 -----* 0.45±0.02 0.68±0.02 
MD_E219K 4 0.45±0.01 0.46±0.02 0.68±0.01 !
Figure 4.5: MD WT - pi-stacking and (Cys179-Cys214) bridge mean values for
each set of simulations.
The β2-α2 loop.
It features a characteristic three-centered aromatic cluster based on the pi-stacking interactions
between Tyr169, Phe175 and Tyr218 (see 4.6 A and 4.5). A side-chain hydrogen bond (HB)
between Tyr169 and Asp178 keeps the stability of this peculiar configuration. Remarkably, this
hydrophobic organization in the β2-α2 loop is similar in the NMR structure (38), as well as
in the recently reported X-ray structures of WT HuPrPs in its monomeric form (145). We
conclude that our computational setup reproduces the key structural facets of this region.
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Figure 4.6: Scheme of key interactions in the systems studies. - A scheme
of the two different structural behaviors identified for MD WT and MD E200K is
visualized (we chose the MD E200K since the structural behaviors of MD Q212P
mutant are similar, see main text). Only the key interactions are reported: the
SBs in α3 and α2, the position of the Tyr169, the HBs and the pi-stackings between
Tyr169, Phe175 and Tyr218.
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4.3.2 HuPrP(E200K).
The 3D structure of the folded domain of this mutant was obtained by replacing Glu200 with a
Lys in the NMR WT structure (Fig. 4.1 B). The overall fold turned out to be similar to that
of the NMR E200K (see 4.2), as well as the MD WT for all the four-independent simulations
of this system. However, the RMSF of the residues belonging to the most flexible regions (the
β2-α2 loop and the α2-α3 region) increased (Fig. 4.3).
The α2-α3 region.
The mutation affected α3, where the mutated residue was located. The Glu200 → Lys200
mutation destroyed the SB interactions characterizing that region and as a consequence the
two-block organization found in the MD WT was lost (Fig. 4.6 B): the absence of Lys204-
Glu200 SB in Block B caused a rearrangement of Lys204 side chain, which interacted now with
Glu207 (see 4.7 and Fig. 4.6 B). The new Lys204- Glu207 SB in block B broke the Arg208-Glu207
and the Arg208-Glu211 SBs in Block A. Indeed, in the most populated cluster, the Arg208-Glu207
and the Arg208-Glu211 SBs were not observed (see 4.7 ). We found the same for all the other
simulations for this system (see 4.7 ).
!! !
Systems MD_E200K 1 MD_E200K 2 MD_E200K 3 MD_E200K 4 
Total population collected 
(%) 82 86 85 83 
Relative population 
collected (%) 73.1 14.2 12.7 59.5 25.5 15.0 87.9 6.9 5.2 56.4 31.6 12.0 
Cluster 1 2 3 1 2 3 1 2 3 1 2 3 
Arg208 -Glu211 0.97 0.84 0.97 0.94 0.38 0.43 0.92 0.91 0.87 0.93 0.82 1.02 
Glu207-Arg208 1.13 1.10 1.13 0.97 0.45 0.69 0.99 1.09 0.87 1.04 1.02 1.06 
Lys204-Glu207 0.95 0.72 0.65 0.36 0.98 0.94 1.04 0.56 0.99 0.94 0.68 0.38 
Glu200/Lys200-
Lys204 1.13 1.22 0.96 0.82 0.70 0.96 0.76 1.20 0.98 0.78 0.94 1.15 
SB
(n
m
) 
Glu146-Lys204 0.50 1.31 1.01 0.35 1.06 0.66 0.45 0.93 0.55 0.82 0.99 1.33 !!!!!!
Figure 4.7: MD E200K SBs - Lys204-Glu200, Lys204-Glu146, Lys204-Glu207,
Arg208-Glu207 and Arg208-Glu211 SBs.
Due to the new SB net configuration, all the five charged residues of helix 3 were totally
exposed to the solvent showing an increased solvent accessible surface (SAS) especially for
Glu211, Arg208, Glu207 and Glu200 (see Fig. 4.8). Remarkably, all of these features were also
observed in the NMR structures.
The χSS in MD E200K was ∼ +90 degrees, as opposed to MD WT where it was ∼ -
90 degrees. As a result, the distance between the Cα atoms of these residues was shorter in
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Figure 4.8: Solvent Accessible Surface(SAS) - SAS of the β2-α2 loop (A)
and the α2-α3 region (B). The color code is the same of the figure in the Main Text:
MD WT: black; MD E200K: red; MD Q212P: green; MD E219K: blue. Notably
each point is mediated on all the simulation for the same system.
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MD E200K than in the MD WT (0.65±0.02 nm and 0.68±0.01 nm respectively, see 4.5 and 4.9).
Although a difference of 0.03 nm between MD WT and MD E200K is small, the same trend was
confirmed in the corresponding NMR structures (0.59±0.01 and 0.68±0.03 nm respectively).
The β2-α2 loop.
Despite the mutated residue belonging to the helix 3, the β2-α2-loop region (residues 160-175)
rearranged (Fig. 4.3). Tyr169 side chain passed from a gauche+ to a trans conformation and
consequently its aromatic ring was solvent exposed (Fig. 4.10 A). This was confirmed by an
increase of about 0.5 nm2 in the SAS of this residue compared to the MD WT (Fig 4.8). Thus,
the characteristic three-centered aromatic cluster (Tyr169, Phe175 and Tyr218), observed in the
MD WT, was no longer present. Only the pi-stacking interaction between Phe175 and Tyr218
was maintained (see 4.9).
Interaction !-stacking (Cys
179-Cys214) 
bridge 
Systems Tyr169-Phe175 (nm) Phe175 - Tyr218 (nm) C"- C"(nm) 
MD_WT 1 0.45±0.02 0.46±0.03 0.68±0.01 
MD_WT 2 0.44±0.02 0.45±0.02 0.68±0.01 
MD_WT 3 0.45±0.02 0.46±0.03 0.69±0.01 
MD_WT 4 0.45±0.02 0.46±0.02 0.68±0.01 !
Interaction !-stacking (Cys
179-Cys214)  
bridge 
Systems Tyr169-Phe175 (nm) Phe175 - Tyr218 (nm) C"- C"(nm) 
MD_E200K 1 0.84±0.07 0.50±0.04 0.65±0.02 
MD_E200K 2 0.72±0.09 0.47±0.03 0.65 ± 0.02 
MD_E200K 3 1.12±0.10 0.46±0.03 0.65±0.02 
MD_E200K 4 0.80±0.15 0.47±0.03 0.65±0.02 !
Interaction !-stacking (Cys
179-Cys214) 
bridge 
Systems Tyr169-Phe175 (nm) Phe175 - Tyr218 (nm) C"- C"(nm) 
MD_Q212P 1 0.86±0.05 0.47±0.03 0.65±0.02 
MD_Q212P 2 0.93±0.18 0.46±0.02 0.65±0.02 
MD_Q212P 3 0.80±0.18 0.46±0.02 0.65±0.01 
MD_Q212P 4 0.90±0.22 0.48±0.04 0.66±0.02 !
Interaction !-stacking (Cys
179-Cys214) 
bridge 
Systems Tyr169-Phe175 (nm) Phe175 - Tyr218 (nm) C"- C"(nm) 
MD_E219K 1 0.44±0.04 0.43±0.02 0.67±0.01 
MD_E219K 2 0.44±0.02 0.46±0.02 0.68±0.01 
MD_E219K 3 -----* 0.45±0.02 0.68±0.02 
MD_E219K 4 0.45±0.01 0.46±0.02 0.68±0.01 !
Figure 4.9: MD E200K - pi-stacking and (Cys179-Cys214) bridge mean values
Finally, Ramachandran angle transition of adjacent residues Ser170 and Asn171, not present
in the WT, were observed. Remarkably, these calculations reproduced the NMR structure
(Fig. 4.10).
We conclude that the NMR structural determinants are reproduced. Therefore, we use our
protocol to predict the structure of HuPrP(Q212P) and HuPrP(E219K).
4.3.3 HuPrP(Q212P).
The overall folded domain was similar to that of WT HuPrP (See 4.2, Fig. 4.1 B). Nevertheless,
based on the RMSF (Fig. 4.3), we observed also in this case that this mutation caused an
increase of the flexibility of the α2-α3 and β2-α2 regions.
The α2-α3 region.
Gln212 replacement with Pro caused the breaking of the HB with Arg208 present in the MD WT
(Fig. 4.6). The loss of the HB caused an increase of the pitch of the helix (Fig. 4.11) and as a
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Figure 4.10: Dihedral Angle transitions in the β2-α2 loop. - A) Conforma-
tion transition of Ser170 and Asn171 in MD E200K and MD Q212P (red and green
points respectively) toward the MD WT (black points). Notably each point is a
mean value calculated on all the simulations for the same system. B) Conformation
transition of Glu168 and Asp167 in MD E219K (blue points) toward the MD WT
(black points). Notably each point is a mean value calculated on all the simula-
tions for the same system. A superimposition of the HuPrP mutant structures on
the MD WT structure in the β2-α2 loop is also reported: the position of Tyr169
is underlined with a mixed tube/cartoon representation. The snapshots reported
correspond to the most populated cluster of one simulation set.
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Figure 4.11: α3 helix pitch of MD WT toward MD Q212P. - The
Cα(Arg208)- Cα(Gln212) distance for MD WT (black-line) and the Cα(Arg208)-
Cα(Pro212) distance for MD Q212P (green-line) are plotted as a function of the
simulated time. The mean values are respectively 0.73±0.04 nm and 0.63±0.02
nm. Notably each point is a mean value calculated on all the simulations for the
same system.
!! !!!
Systems MD_Q212P 1 MD_Q212P 2 MD_Q212P 3 MD_Q212P 4 
Total population collected 
(%) 83 87 83 82 
Relative population 
collected (%) 55.6 30.2 14.2 69.6 17.4 13.0 76.0 14.2 9.8 72.0 16.4 11.6 
Cluster 1 2 3 1 2 3 1 2 3 1 2 3 
Arg208 -Glu211 1.09 0.91 0.99 1.04 1.10 0.69 0.38 0.97 0.71 0.79 0.52 0.98 
Glu207-Arg208 0.90 0.92 0.94 0.82 0.81 0.44 0.39 0.74 1.11 0.93 0.40 0.93 
Lys204-Glu207 1.03 0.94 0.52 0.38 0.92 0.84 0.97 0.98 0.40 0.92 0.52 0.82 
Glu200/Lys200-
Lys204 0.66 0.64 1.05 1.03 0.76 0.73 0.64 0.38 0.95 1.01 1.05 0.58 
SB
(n
m
) 
Glu146-Lys204 0.45 0.81 0.79 1.00 0.42 0.72 1.08 1.13 1.14 0.60 1.30 0.89 !!!!
Figure 4.12: MD Q212P SBs - Lys204- Glu200, Lys204-Glu146, Lys204-Glu207,
Arg208-Glu207 and Arg208-Glu211 SBs.
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result, Arg208 rearranged: it weakened its SB with Glu211 and Glu207 and formed, at times, a
SB with Glu146 (see 4.12). Thus, also Glu146- Lys204 SB weakened.
The cluster analysis reflected that situation: on three main clusters (that collect the 86%
of population), the Glu146-Lys204 SB was never found (see 4.12). The final SB pattern was
strikingly similar to that of HuPrP(E200K), with an increasing of SAS especially for Glu211,
Glu207 and Lys204. The latter became totally exposed to the solvent.
Finally, we checked the Cα(Cys179)- Cα(Cys214) distance (d=0.65±0.02 nm). This was
shorter than that in MD WT (see 4.13 ), and similar to that in MD E200K. Also here, Cys179
switched toward a gauche+ conformation as found for the HuPrP(E200K) mutant.
The β2-α2 loop.
This rearranged very similarly to the loop in MD E200K: the Tyr169 side chain switched from
a gauche+ to a trans conformation, becoming exposed to the solvent (Fig. 4.10). In particular,
the SAS of this residue increased of about 0.5 nm2 relative to MD WT (Fig 4.8 B). Also here,
the characteristic three-centered aromatic cluster (Tyr169, Phe175 and Tyr218) was no longer
present (see 4.13). Remarkably Ser170 and Asn171 rearranged as in MD E200K mutant (Fig.
4.10 A).
Interaction !-stacking (Cys
179-Cys214) 
bridge 
Systems Tyr169-Phe175 (nm) Phe175 - Tyr218 (nm) C"- C"(nm) 
MD_WT 1 0.45±0.02 0.46±0.03 .68±0.01 
MD_WT 2 0.44±0.02 0.45±0.02 0.68±0.01 
MD_WT 3 0.45±0.02 0.46±0.03 0.69±0.01 
MD_WT 4 0.45±0.02 0.46±0.02 0.68±0.01 !
Interaction !-stacking (Cys
179-Cys214)  
bridge 
Systems Tyr169-Phe175 (n ) Phe175 - Tyr218 (nm) C"- C"(nm) 
MD_E200K 1 0.84±0.07 0.50±0.04 0.65±0.02 
MD_E200K 2 0.72±0.09 0.47±0.03 0.65 ± 0.02 
MD_E200K 3 1.12±0.10 0.46±0.03 0.65±0.02 
MD_E200K 4 0.80±0.15 0.47±0.03 0.65±0.02 !
Interaction !-stacking (Cys
179-Cys214) 
bridge 
Systems Tyr169-Phe175 (nm) Phe175 - Tyr218 (nm) C"- C"(nm) 
MD_Q212P 1 0.86±0.05 0.47±0.03 0.65±0.02 
MD_Q212P 2 0.93±0.18 0.46±0.02 0.65±0.02 
MD_Q212P 3 0.80±0.18 0.46±0.02 0.65±0.01 
MD_Q212P 4 0.90±0.22 0.48±0.04 0.66±0.02 !
Interaction !-stacking (Cys
179-Cys214) 
bridge 
Systems Tyr169-Phe175 (nm) Phe175 - Tyr218 (nm) C"- C"(nm) 
MD_E219K 1 0.44±0.04 0.43±0.02 0.67±0.01 
MD_E219K 2 0.44±0.02 0.46±0.02 0.68±0.01 
MD_E219K 3 -----* 0.45±0.02 0.68±0.02 
MD_E219K 4 0.45±0.01 0.46±0.02 0.68±0.01 !
Figure 4.13: MD Q212P - pi-stacking and (Cys179-Cys214) bridge mean values
We conclude that the structural features of HuPrP(Q212P) are similar to those of HuPrP(E200K).
This is really unexpected, since the mutation is different in chemical properties and it is localized
in a different part of the third helix.
4.3.4 HuPrP(E219K).
The overall folded domain remained essentially similar to the WT HuPrP ( see 4.2, Fig. 4.1
B). Nevertheless, it had a widespread influence on the flexibility of the same two regions (β2-α2
and α2-α3) already observed in the pathogenic mutants (Fig. 4.3).
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Systems MD_E219K 1 MD_E219K 2 MD_E219K 3 MD_E219K 4 
Total population collected 
(%) 76 78.2 80 84 
Relative population 
collected (\%) 59.2 30.7 10.1 72.0 19.4 8.6 59.8 30.5 9.7 60.6 29.4 10.0 
Cluster 1 2 3 1 2 3 1 2* 3 1 2 3 
Arg208 -Glu211 0.37 0.39 0.38 0.38 0.38 0.43 0.38 0.99 0.43 0.51 0.50 0.51 
Glu207-Arg208 0.34 0.51 0.36 0.44 0.45 0.45 0.41 0.83 0.42 0.35 0.36 0.36 
Lys204-Glu207 0.89 1.05 0.97 0.9 1.01 0.99 1.08 0.84 0.60 0.97 0.99 0.88 
Glu200/Lys200-
Lys204 0.72 0.43 1.00 0.59 0.36 0.82 0.92 0.36 1.30 0.79 0.35 0.94 
SB
(n
m
) 
Glu146-Lys204 0.75 0.83 0.32 1.23 0.82 0.48 0.38 0.86 0.97 0.70 1.11 0.47 !"!#!$%&&'(')*! +,! -.)&.(/0*%.)!102! &.3)$! %)! *4'! 2'-.)$! -532*'(6! "#$%&'! %)*'(0-*2!1%*4!()*+,-! 7$+,89:;<!)/=! %)2*'0$!.&! %)*'(0-*%)>!1%*4!./0+,&:! ?)*'('2*%)>5@A! *4%2! -.)&.(/0*%.)!102! &.3)$! 052.! &.(! .)'!.&! *4'!-532*'(2!%)!*4'!BC!2@2*'/A!3)$'(5%)%)>!0>0%)!*4'!2%/%50(%*%'2!D'*1'')!*4'2'!*1.!2@2*'/2:!!!Figure 4.14: MD E219K SBs - Lys204- Glu200, Lys204-Glu146, Lys204-Glu207,
Arg208-Glu207 and Arg208-Glu211 SBs
The α2-α3 region.
Glu219 is located at the end of α3 and its mutation did not interfere with the SB pattern of
helix 3 (see 4.14): it remained identical to the MD WT.
The Cα(Cys179)- Cα(Cys214) distance was also similar (d=0.67±0.02 nm) to that of
MD WT and, consequently, longer than that of the pathogenic mutants (see 4.16).
The β2-α2 loop.
The three-centered aromatic cluster based on the pi-stacking interactions between Tyr169,
Phe175 and Tyr218 was maintained in three of the four simulation performed for this sys-
tem. More in detail, Tyr169 side chain pointed toward the bulk of the protein as in MD WT
(see Fig. 4.10 B and 4.16), however it H-bonded to Arg164 instead of Asp178, as in MD WT
(Fig. 4.15).
In one of the other three simulations, a different configuration for Tyr169 is observed. The
residue is sandwiched between Tyr218 and Tyr225, pointing, as in the other cases, towards the
bulk of the protein (see 4.16 and side Figure). Glu168 and Asp167 rearranged to a conformation
other than that of the pathogenic mutants (Fig. 4.10 B). Ser170 and Asn171 instead had the
same conformation as in MD WT. We conclude that the HuPrP(E219K) polymorphism leads
to structural determinants close to those of WT HuPrP and opposed to HuPrP(Q212P), and
HuPrP(E200K), although it features a mutation close in space to that of HuPrP(Q212P), and
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Figure 4.15: Tyr169 HBs. - Tyr169- Asp178 HB for MD WT, Tyr169- Asp178 and
Tyr169- Arg164 HBs for MD E219K are represented as a function of the simulated
time. Notably this configuration is the same in all the simulation sets. Only an
exception is found and it is described in the text
is similar in chemical type to HuPrP(E219K).
4.4 Discussion
It has been postulated that the primary role of inherited point mutations is to increase the
likelihood of misfolding by the thermodynamic destabilization of PrPC (150), (223), triggering
in turn an abnormal interaction with other not yet identified co-factors (124; 225), or promoting
an aberrant accumulation inside the cell (15). This hypothesis is based on the experimental
evidence that the effect of inherited point mutations on the HuPrP structure is the spontaneous
formation of PrPSc in the brain (202). Therefore, structural studies with HuPrP variants con-
taining familial mutations should provide important clues regarding the molecular basis of the
disease. One of the crucial questions is the identification of the regions involved in the tran-
sition process from -helical to -sheet rich structure. Several experimental studies lead to the
proposal that the α2-α3 region plays a crucial role during the conversion from PrPC to PrPSc
(2; 138; 139; 154). We have presented here a MD simulations protocol where starting from
the globular domain (residues 125-228) of WT HuPrP NMR structure (38; 247), we were able
to predict structural facets in aqueous solution of two pathological mutations, HuPrP(E200K)
(252) and HuPrP(Q212P)(193) causing familial CJD and GSS respectively (202), and of the
protective polymorphism HuPrP(E219K) (210; 211). All these variants are located in the
globular domain of HuPrP. Our computational setup has been established by comparing the
structural determinants of MD WT and MD E200K with the corresponding NMR structures.
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Interaction !-stacking (Cys
179-Cys214) 
bridge 
Systems Tyr169-Phe175 (nm) Phe175 - Tyr218 (nm) C"- C"(nm) 
MD_E219K 1 0.44±0.04 0.43±0.02 0.67±0.01 
MD_E219K 2 0.44±0.02 0.46±0.02 0.68±0.01 
MD_E219K 3 -----* 0.45±0.02 0.68±0.02 
MD_E219K 4 0.45±0.01 0.46±0.02 0.68±0.01 ! "#!$%&&'(')*!+,)&%-.(/*%,)!&,(!01(234!%5!6'('!,75'(8'$9!06'!('5%$.'!:%'5!7'*;'')!01(<2=!/)$!01(<<>9!?''!@%-.('!,)!*6'!5%$'9!
Figure 4.16: MD E200K - pi-stacking and (Cys179-Cys214) bridge mean values
To improve the statistics of our procedure, four independent, 50 ns long MD simulations have
been run for each system (800 ns in total). The results turn out to be very similar across the
four runs. The most remarkable result was that the pathogenic mutations affected the same
structural regions of the HuPrP, regardless of mutant positions, chemical properties and clinical
features. These regions are the α2-α3 region and the β2-α2 loop. The residues belonging to α2-
α3 loop region and the β2-α2 loop are more flexible than the correspondent ones of WT HuPrP.
This was in agreement with the fact that the same regions underwent an essentially complete
isotope exchange within less than 30 min, suggesting relatively large conformational flexibility
(247). In this respect, it is really remarkable that NMR studies have shown that a completely
different pathogenic mutation, H187R, has the same effect on the highly homologous mouse
prion protein (17). The larger flexibility of the α2-α3 region, observed in the HuPrP(E200K)
and HuPrP(Q212P) relative to WT HuPrP might be related to the loss of specific SBs. This is
fully consistent with the suggestion, based on in silico studies, that the α-helical fold of α2-α3
is assisted by intermolecular interactions other than those of the α-helices themselves (73? ),
as already observed in other α-helical proteins (123; 245). The residues involved in the SBs
are clearly very relevant: they are highly conserved and their absence is linked with pathogenic
behaviors (2). In spite of their clear importance, so far, a role for protein fibrillation had only
been suggested (2). Our calculations corroborate this suggestion. Interestingly, the loss of SBs
is associated with a change of the structural parameters of the only disulphide bridge of the
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protein, in full agreement with the available experimental data (38; 247; 252). The larger flexi-
bility of the β2-α2 loop is due to different features depending on the mutations. In the healthy
variant of HuPrP (i.e. MD WT and MD E219K), the Tyr169 side chain was in gauche+ confor-
mation pointing towards the bulk of the protein. In the pathogenic mutants (i.e. MD E200K
and MD Q212P) such side chain was in a trans conformation with the consequent exposure
of the aromatic ring towards the solvent. Only in these cases the characteristic three-centered
aromatic cluster (Tyr169, Phe175 and Tyr218), observed in the MD WT, were no longer present.
Interestingly, the crystal structures of HuPrP(D178N) and HuPrP(F198S) mutants effectively
showed similar orientation of Tyr169 side chain outside the globular part.(145) Tyr169 is in
the region that might modulate the binding of a hypothetical facilitator of prion conversion
involved in the development of TSE (124; 225); thus such conformational change may cause an
altered protein-protein interactions. We therefore put forward the hypothesis that the presence
of Tyr169 outside the loop is a key pathological structural feature. In summary, we suggest
that the strongest effect of the HuPrP mutations in the globular domain might always involve
the same region of the protein and always follow the same mechanism: on one hand, altering
the conformation of the β2-α2 loop region and modifying the exposed hydrophobic surface,
and on the other, altering the long-range interaction in the 2-3 region. Moreover, this study
sheds new light on the molecular basis of inherited prion diseases, introducing novel structural
features, which are of great importance for our understanding of these disorders and of the
earliest molecular events leading to the conformational transition of PrPC into a β-sheet-rich
fold. Our protocol could be used as a useful high-throughput approach to investigate and
predict structural facets of HuPrP disease-causing mutations when increasing the statistics of
mutation studied. A statement of warning should be made. Because of the presence of the
long unstructured N-term segment, the implications of our findings for the full-length protein
in vitro must be taken with great caution. It is possible that the unstructured PrP segment
might alter the structure and the stability of the protein in a rather drastic way.
After I had carried out this MD study, Ilk et al. (115) reported the NMR solution structure
of the truncated recombinant human PrP from residue 90 to 231 carrying the HuPrP(Q212P)
mutation. My predictions are in complete agreement with the NMR data. In particular, Tyr169
is completely exposed to solvent and the β2-α2 loop is highly flexible in both computation and
experiment (data not shown). This further strengthens the validity of my computational protocol.
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Figure 4.17: HuPrP(90231, M129, Q212P) - pdb id 2KUN; Figure 5 A taken
from Ilk et al. (115).
61

5Common structural traits across
all prion-disease linked
mutations.
5.1 Introduction.
In the previous chapter, we have shown that two pathological mutations, HuPrP(Q212P) and
HuPrP(E200K) impact on the flexibility of β2-α2 loop, on the rearrangement of Tyr169 which
belongs to that region, and, finally, on the flexibility of the α2-α3 region of the globular domain.
The latter two are among most flexible regions of the protein (138; 139; 154), (247).), with the
largest tendency towards oligomerization in vitro (2; 45). This has lead to the hypothesis
that pathogenic conversion process could be related to the global conformational fluctuation of
PrPC (138; 139).
Based on all of these facts, we ask ourselves a key question: Do then all of disease-linked
mutations have similar fingerprints as those of HuPrP(Q212P) and HuPrP(E200K)? We have
attempted at addressing this issue by carrying out MD simulations on all mutations in the
globular domain using the highly efficient computational protocol presented in the previous
chapter.
5.2 Incidence and location of mutations of the
structure
Let us first review again the disease-linked mutations involving residues of the globular domain
of the PrPC , for which experimental structural information is available. We report the incidence
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of all of them (134) and we show their localization in the PrPC . Some pieces of this information
have been already reported in Chapter 2.
Figure 5.1: Hu PrP Mutants - Location of the mutations in the the globular
domain of PrPC .
More than 30 mutations have been reported (230). The available data are standardized data
on TSEs between 1993 and 2002 in the framework of the EUROCJD collaborative surveillance
project (134). EUROCJD reports 12 mutations in the globular domain and 2 mutants belongs
to N-terminal region. It misses only mutations which very rare and/or are restricted to specific
populations (133). The commonest mutation is HuPrP(E200K), followed by HuPrP(V210I)
and HuPrP(D178N-129M) (Tab. 5.1). Two mutations involve residues located in 1 (Y145stop
and R148H), three in the 1 (G131V, S132I, A133V) and one in the 2 (Q160stop) (Fig. 5.1).
All the other mutations in the globular domain are located in the α2-α3 region. In particular,
the HuPrP(E200K), HuPrP(V210I) and HuPrP(D178N-129M) ones with the highest incidence
are the located there.
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5.3 Methods.
The computational protocol used is the same used in the previous chapter, except that we
decided to perform a single calculation for each mutant instead of four. Indeed, from one
hand we have observed that the changes on passing from one simulation to another are really
very small. From the other, performing four simulations for all of the mutants would have been
highly expensive. Some of the calculations have been performed by my colleague Xiaojing Cong
here in SISSA. Calculated properties. The Connelly Solvent Accessible Surface Area (SASA)
(see Method section) was calculated by a standard GROMACS utility, which implements the
double cube lattice method (78) with a probe radius of 1.4 A. Since the SASA of Tyr169 WT
PrPC is 0.40 ± 0.02 (nm2), we considered the tyrosine Exposed (E) with SASA ≥ 0.5 nm2,
Very Exposed (VE) with SASA ≥ 0.6 and Outside (O) when SASA≥ 1 nm2 and Tyr169 goes
completely outside of the β2-α2 loop. The distance between Tyr169 and Phe175 is defined
here as the distance between the centers of mass of atoms belonging to the aromatic rings.
That between Tyr225 and Met166 is defined here as the distance between that between Try225
aromatic ring and Met166 sulfur. The root mean square fluctuation (RMSF) of atomic positions
was calculated with respect to the HuPrP(WT) structure at pH 7 (247).
5.4 Result and Discussion.
Here we investigate whether the key structural facets observed in the diseases linked mutations
in the previous chapter (exposure of Tyr169, Root Main Square Fluctuations (RMSF) of β2-α2
loop and α2-α3 regions) emerge also for all of the other mutants.
5.4.1 Tyr169 Exposure.
Tyr169 is located in a surface epitope formed by the β2-α2 loop and parts of helix α3 Fig. 5.2.
In the previous chapter, we have shown that (i) in WT and in the protective polymorphism
HuPrP(E219K), the Tyr169 side chain points toward the bulk of the protein, forming a pi-
stacking interaction with Phe175 (ii) In the two pathogenic mutants E200K and Q212P Tyr169
side chain is solvent exposed. The Phe175- Tyr169 pi-stacking interactions are lost. Also all
of the other variants with reported high incidence besides HuPrP(E200K) (HuPrP(V210I),
HuPrP(D178N-129M) (134)) feature large rearrangements of Tyr169 (Tab. 5.1 and Fig. 5.2-
B). In addition, the Phe175- Tyr169 pi-stacking interactions are lost. This leads to a complete
exposure of this residue to the solvent. The same features, albeit less pronounced, are observed
for all of the other disease-linked mutations. Tyr169 is more exposed to the solvent relative to
WT (Tab. 5.1 and Fig. 5.2-C). The Phe175-Tyr169 pi-interactions are lost for the mutants which
experience very large solvent exposure of Tyr169 (VE in 5.1). Interestingly, the Tyr169-bearing
epitope was previously suggested to be a recognition site in a mouse/human chimera PrPC
for a potential chaperone, so far not identified. This chaperone assists the conversion of PrPC
into PrPSc (124; 225). Hence, the rearrangement of this residue might affect binding to this
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pi-stacking Aromatic-Sulfur
SYSTEM Incidence Available Structure ∗∗ Tyr169 Esposure Tyr169-Phe175 Tyr225 - Met166
nm nm
WT - NMR (38; 252) Not Exposed 0.45±0.02 0.49±0.07
G131V-129M - 0.2 E 0.52±0.02 0.79±0.08
S132I-129M - - VE 0.57±0.07 0.48±0.08
A133V-129M - - E 0.48±0.03 0.78±0.29
R148H-129M - - E 0.48±0.02 0.59±0.17
D178N-129M 14.1 ∗ X Ray Dimer (145) O 1.13±0.02 0.56±0.20
D178N-129V 3.5 ∗ X Ray Dimer (145) O 1.05±0.02 0.56±0.20
V180I-129M 0.7 - VE 0.61±0.11 0.93±0.26
T183A-129M - - VE 0.74±0.03 0.66±0.14
T183A-129V - - O 1.12±0.11 0.98±0.20
H187R-129V - - O 0.71±0.10 0.68±0.17
T188K-129M - - E 0.52±0.03 0.80±0.23
T188A-129M - - VE 0.73±0.04 0.98±0.27
T188A-129V - - VE 1.12±0.05 0.45±0.05
T188R-129V - - E 0.53±0.03 0.59±0.14
T193I-129M - - E 0.51±0.08 0.60±0.17
E196K-129M 1.1 - E 0.49±0.03 1.04±0.30
F198S-129V - ∗ X Ray Dimer(145) O 0.87±0.05 0.62±0.20
E200K-129M 38.5 NMR(252) O 0.84±0.07 0.60±0.20
D202N-129M - - VE 0.61±0.12 0.65±0.28
D202N-129V - - E 0.51±0.02 0.53±0.09
V203I-129M 1.1 - E 0.56±0.06 0.83±0.44
R208H-129M 0.4 - E 0.48±0.03 0.62±0.07
R208H-129V - - E 0.59±0.08 0.50±0.11
V210I-129V 15.2 - O 1.12±0.07 0.70±0.20
E211Q-129M 0.9 - VE 0.73±0.03 0.90±0.30
Q212P-129M - NMR(115) O 0.86±0.05 0.55±0.30
Q217R-129V - - E 0.48±0.02 0.49±0.05
E219K-129M - - Not Exposed 0.44±0.04 0.49±0.08
∗ The structure is in a dimeric conformation (145) ∗∗ Exposed (E) with SASA ≥ 0.5 nm2, Very Exposed (VE) with SASA ≥
0.6 nm2 and Outside (O) when SASA ≥ 1 nm2 and Tyr169 is outside of the 2-2 loop as in Fig. 5.2
Table 5.1: Table of properties in HuPrP Mutants - Disease-linked mutations
for which structural information is available either from NMR and X-ray studies
or from the present MD study. The latter is the MD average structure. Several
properties are reported: (i) Incidence; (ii) Structure from which data are extracted
from; (iii) Tyr169 Exposure to the solvent; (iv) Tyr169-Phe175 pi-stacking distance;
(v) Tyr225 ring - Met166 sulfur distance.
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Figure 5.2: Binding Epitope - Epitope formed by the β2-α2 loop and
parts of helix α3. A) WT. B) HuPrP(E200K). Similar conformations are seen
in HuPrP(D178N-129M/V), HuPrP(T183A), HuPrP(H187R), HuPrP(F198S),
HuPrP(E200K), HuPrP(V210I), HuPrP(Q212P). C) HuPrP(Q217R). Similar con-
formations are seen in all remaining mutants.
chaperone and conversion into PrPSc in all-disease linked mutations. At the speculative level,
we add here that such change of binding might play a role for the experimentally observed
increase in fibrillation of such variants.
5.4.2 Flexibility of the β2-α2 loop and of the α2-α3 region.
The flexibility of these region larger in all the disease-linked mutants than in WT 1.
The increased flexibility of α2-α3 loop is in fact (not-surprisingly) accompanied with a
change of position of the α2 and α3 helices -the key region of the protein for fibrillation (45))
- relative to WT. Indeed, in most of the mutants 2, Tyr225, belonging to helix α3, does not
form contacts with Met166, belonging the β2-α2 loop. Consequently, part of helix α3 is opened
and accessible to solvent (Fig. 5.2). This feature is consistent with what found in the NMR
structure of HuPrP(Q212P-129V) (115). Because, the α2-α3 helices are highly fibrillogenic
(2; 45) and their fold is highly stabilized by the protein frame (73; 74), we suggest here that
the changes in structure and conformational fluctuations of the α2-α3 loop and α2, α3 helices
might be an important factor for the PrPC tendency to oligomerize.
1Interestingly also in the protective polymorphism HuPrP(E219K) the flexibility of the β2-
α2 and α2-α3 loops is larger respect the WT. Nevertheless, here the rearrangement of these
region is completely different from the ones characterizing the pathogenic mutants (see 4.10)
2In particular, in all of those variants associated with the largest incidence
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Figure 5.3: RMSF of HuPrP Mutant - RMSF of HuPrP(WT),
HuPrP(E219K) (protective polymorphism), and all known disease-mutants cal-
culated for each residue in the globular domain. See Figure 4.3
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The increased flexibility of the β2-α2 loop might also play a role for PrPC fibrillation prop-
erties. Indeed, the susceptibility towards prion diseases has been correlated with the plasticity
of the epitope formed by β2-α2 loop and the C-terminal part of the α3 helix (See (54) and
Appendix C).
5.5 Concluding remarks.
Taken together, our calculations carried out on as many as 28 disease-linked mutations, show
that mutations are associated with three structural features, which could play an important
role for their known fibrillation properties in vivo. We have shown that HuPrP diseases-linked
mutations in the globular domain are associated with the same structural fingerprints: from
on one hand, they alter the conformation of the β2-α2 loop region and modify the exposed
hydrophobic surface with the exposure of the Tyr169. Form the other hand they alter the long-
range interaction in the α2-α3 region. All of these features may play a role for prion/cognate
protein recognition (124; 225), and in turn for the fibrillation properties of PrPC .
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6Docking Ligands on Protein
Surfaces: The Case Study of
Prion Protein.
Molecular docking of ligands targeting proteins undergoing fibrillization in neurode-
generative diseases is difficult because of the lack of deep binding sites. Here we
extend standard docking methods with free energy simulations in explicit solvent to
address this issue in the context of the prion protein surface. We focus on a spe-
cific ligand (2-pyrrolidin-1-yl-N-[4-[4-(2-pyrrolidin-1-yl-acetylamino)-benzyl]-phenyl]-
acetamide), which binds to the structured part of the protein as shown by NMR
(Kuwata K, et al. (2007) Proc Natl Acad Sci U S A 104:11921-11926). The calcu-
lated free energy of dissociation (7.8 ± 0.9 kcal/mol) is in good agreement with the
value derived by the experimental dissociation constant ( Kd= 3.9 µM, corresponding
to ∆ G0 = -7.5 kcal/mol). Several binding poses are predicted, including the one
reported previously. Our prediction is fully consistent with the presence of multiple
binding sites, emerging from NMR measurements. Our molecular simulation-based
approach emerges therefore as a useful tool to predict poses and affinity of ligands
binding to protein surfaces.
6.1 Introduction
Recent developments in molecular docking protocols (MDPs) allow one to predict accurately
ligand poses in their target binding sites (11; 129). In several cases, the reason of their success
lays in the coupling of traditional scoring function-based approaches with molecular simulation
approaches (9) (such as soft harmonic modes (160), molecular dynamics simulations (158; 185)
and relaxed complex method (151; 161)). The latter introduce conformational flexibility of the
target, accounting for the fact that proteins are in constant motion between different confor-
mational states (40). These may be locally altered when a ligand is bound (40).
In spite of these successes, there are still many important cases for which MDPs are chal-
lenged. These include the prediction of the poses of transition-metal and/or alkylating drugs,
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of ligands causing large structural changes, and of ligands not binding to specific pockets.
The latter is common to proteins undergoing fibrillization in neurodegenerative diseases. Here
we propose an enhanced molecular docking protocol (EMD in Figure 6.1 ) that extends MDPs
with free energy simulations in explicit solvent to predict the structure and energetics of ligands
binding to protein surfaces.
Protein misfolding followed by self-association and subsequent deposition has been ob-
served in the brain tissues of patients affected by different neurodegenerative disorders. Diverse
proteins have been shown to follow this process, including amyloid-β (in Alzheimer disease),
α-synuclein (in Parkinson disease), huntingtin (in Huntington disease), and prion protein (in
prion diseases) (35; 44; 216). The protocol we propose here may be exploited in these cases
for the design of ligands that, by stacking onto protein surfaces, may disrupt protein-protein
interactions and thus inhibit protein self-assembly.
In this study, we apply our EMD protocol in the context of the cellular form of human prion
protein (HuPrPC), responsible for TSE development (see ch. 3), for which neither an early
diagnosis nor a cure is currently available (228). Therefore, there is great interest in designing
ligands binding to HuPrPC , which may interfere with its conversion and with the interaction
with other self-aggregating proteins, such as amyloid-β (144).
Recently, the ligand GN8 (2-pyrrolidin-1-yl-N-[4-[4-(2-pyrrolidin-1-yl-acetylamino)-benzyl]-
phenyl]-acetamide,1 (in Figure 6.2) (140) has been shown to bind Mouse PrP (MoPrPC)
in the µM range. MoPrPC is highly similar to the HuPrPC . The sequence similarity is
as high as 98% and the root mean square difference (RMSD) of the backbone between the
MD structures of HuPrPC (PDB code: 1HJM) (38) is the same (0.26 ± 0.02 nm) as that
between the NMR structures of HuPrPC and MoPrPC (PDB code: 1AG2) (203) (0.27 nm).
Therefore, significant changes of the structure on passing from the mouse to the human protein
are not expected. For the 1-MoPrPC adduct, NMR chemical shifts perturbations of MoPrPC
on protein residues induced by ligand binding have been reported (140). These affect most
significantly amino acid residues on one side of the protein surface (Arg156, Asn159@H1-S2
loop, Lys194@H2, Glu196, Thr199@H2-H3 loop and Val210@H3). In addition, Val189 and
Thr192, located on the other side of the PrPC surface, are also perturbed (Figure 6.4 A). All
these residues are conserved on passing from MoPrPC to HuPrPC . These perturbations have
been ascribed to ligand binding, suggesting that multiple binding sites may be present. An
ad hoc model of the 1-MoPrPC adduct, constructed by docking and energy minimization,
exhibited a single binding mode of GN8 connecting Asn159 and Glu196 (140). Subsequent
quantum-mechanical studies (116), based on this model, pointed out that these two residues,
along with Gln160 and Lys194, are important for the binding. However, such single binding
mode was not consistent with the presence of the contacts between the ligand and Val189,
Thr192 and Thr199.1
The proposed EMD protocol turns out to provide structural prediction consistently with
1A similar NMR study to map prion protein binding sites has been made only for another
ligand, quinacrine (237). The latter, however, has been later suggested not to bind to PrPC
but rather to PrPSc, or other chemical chaperons involved in the prion propagation (127).
72
6.1 Introduction
Figure 6.1: EMD - Enhanced Molecular Docking. MDPs are used to guess puta-
tive ligand binding regions on target surfaces, based on structural information on
the two separated moieties. Structural information on the target may come from
experiment and, in some cases, also from molecular simulation. Ligand may be
docked onto the entire structure (like in this work) or on a putative binding site.
Cluster analysis are used to group MD conformers and/or ligand/target adducts
into representative structures. In the EMD approach, MD simulations may be used
to relax the structures and to investigate the role of hydration. Enhanced sam-
pling simulation techniques in explicit solvent allow to explore the ligand binding
space and to predict free energy of binding. The key ingredient of the protocol
proposed in Figure 6.1 is given by the type of free energy approach used. Sev-
eral powerful methods are available for predicting ligand binding free energies by
means of molecular simulation (88; 205). However, predictions have been made
so far to targets with binding sites well characterized by X-ray crystallography
or NMR experiments. Here we use the metadynamics (141) approach in its bias
exchange variant (191). Metadynamic (141) has recently been shown to uncover
molecular and energetic aspects protein flexibility (148). This approach provides
the free energy as a function of several reaction coordinates (such as geometrical
distances, polar contacts, and water-mediated interactions), which characterize the
ligand binding to its target and its dissociation from it (33; 82; 87; 232). Although
GN8-PrPC interactions energies have been provided by quantum chemical methods
(116), no calculation of free energy has been so far reported. As several other tech-
niques (205), it may allow also to simulate the whole molecular recognition process.
This in turn may allow characterizing multiple binding sites of the ligand onto the
proteins surface, such as those emerging from NMR in the 1-MoPrPC complex.
Comparison against experimental data in this case structural information inferred
by NMR chemical shift perturbations as well as with affinity measurements allows
to validate the protocol (140)
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Figure 6.2: GN8 - (2-pyrrolidin-1-yl-N-[4-[4-(2- pyrrolidin-1-yl-acetylamino)-
benzyl]-phenyl]-acetamide) molecule.
the NMR data and affinity in agreement with experimental data. The EMD protocol emerges
therefore as a useful approach to investigate ligands sticking on protein surfaces.
6.2 Computational Details
6.2.1 Identification of binding sites.
The residues interacting with1are located in HuPrPC C-term, for which the NMR structure
is available (residues 125-228, PDB ID: 1HJM) (38). Protonation states were assigned by the
web server H++36 assuming pH 7.4. Putative binding sites were identified by (i) molecular
simulations (using the GROMACS package (27) and (ii) docking procedure (using the GOLD
(121; 234) and the Autodock programs (171)).
(i) Molecular simulations. The protein was inserted into a cubic box of water
molecules, ensuring that the solvent shell would extend for at least 0.8 nm around the system.
Three sodium counterions were added. The AMBER99 force field (41; 242) was used for the
protein. Sodium ions were modeled with the AMBER-adapted Aqvist potential (1). The water
molecules were described by the TIP3P model (122). The system was minimized imposing
harmonic position restraints of 1000 kJmol-1nm-2 on solute atoms, allowing the equilibration
of the solvent without distorting the solute structure. After an energy minimization of the
solvent and the solute without harmonic restraints, the temperature was gradually increased
from 0 to 298 K. This was performed by increasing the temperature from 0 to 298 K in 12
steps in which the temperature was increased by 25 K in 100 ps of MD. Constant temperature-
pressure (T=298 K, P=1 bar) 20-ns dynamics was then performed through the Nos-Hoover
(110; 180) and Andersen-Parrinello-Rahman (181; 188) coupling schemes. Periodic boundary
conditions were applied. The final simulation box equilibrated at around 6.69 x 6.69 x 6.69
nm. Long-range electrostatic interactions were treated with the particle mesh Ewald (PME)
(66; 80) method, using a grid with a spacing of 0.12 nm combined with a fourth-order B-spline
interpolation to compute the potential and forces in between grid points. The cutoff radius
for the Lenard-Jones interactions as well as for the real part of PME calculations was set to
0.9 nm. The pair list was updated every 2 steps, and the LINCS algorithm (106) was used to
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constrain all bond lengths involving hydrogen atoms allowing us to use a time step of 2 fs. The
MD trajectory of prion protein alone was clustered with the gromos method (67) and as result
20 different conformations were obtained, which were used along with the NMR structure for
docking of compound 1.
(ii) Docking. Titration curves for compound1in bulk solution were calculated by the
ChemAxon software (48) showing that this molecule is present in two protonation states at
pH=7.4: neutral (10) and monoprotonated (1+); while at pH=4.5 it exists mostly in the dipro-
tonated form (12+) (Figure 6.2 and 6.3).
Figure 6.3: Titration curve of GN8 - Titration curve of GN8 as calculated by
the ChemAxon software (10). At the pH of the Kd measurements (140), GN8 is
present in neutral (10) and monoprotonated (1+) states. At the pH of the NMR
measurements (140), it exists also in diprotonated (12+) form. The two pH values
are indicated in the figure.
This method has been used because it appears to be rather reliable: in a calculation of
pKa of 1000 molecules, less than 0.5 % calculations turned out to differ by more than 0.5 pH
unit from the experimental value (48). Since the acidity of compound1is expected to change
in the proximity of the protein, electrostatic potential calculations in implicit solvent (18) were
addressed for the prion protein in two different conditions: pH=4.5 for NMR measurements
conditions and pH=7 for affinity measurements conditions. The electrostatic potential surfaces
were calculated using the APBS package (18) and visualized with VMD (114). The calculation
parameters were 0.3 grid spacing, 1293 meshes, solvent and protein dielectrics of 78.54 and
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40, respectively. All three protomers underwent geometry optimization at the B3LYP/6-31G**
level of theory by means of the Gaussian03 software (g03) (85). The optimized structures, 10, 1+
and 12+, were docked to the NMR structure of HuPrPC and to its 20 different conformations,
as obtained after the cluster analysis of the MD trajectory. The GOLD 3.1 (121; 234) and
Autodock 3.0.5 (171) programs were used. In GOLD, the docking area was defined as a sphere of
3.5 nm radius around the His187, so that the whole protein was screened. The ChemScore (CS)
(177) and GoldScore (GS) (121) scoring functions were used for ranking. For each protomer
and scoring functions, 100 docking runs were performed. In Autodock (171), a Lamarckian
genetic search algorithm was used to identify low energy binding sites and orientations of 1
protomers. Binding modes were ranked by a scoring function implemented in the Autodock. A
point grid with a spacing 0.0475 nm was used. Point grid was centered to the center of mass
of the protein, its dimensions were 12.6 nm x 12.6 nm x 12.6 nm. Gasteiger atom charges were
assigned to the protein atoms using AutoDockTools. Water molecules were excluded from the
protein before docking. 100 randomly seeded runs were performed. The binding poses were
identified by AClAP 1.0 clustering procedure (31).
6.2.2 Hydration and thermal stability of 1-HuPrPC adducts.
10-ns MD simulations of the adducts (HuPrPC-10, HuPrPC-1+ and HuPrPC-12+) allowed
for a proper hydration of the system and for identification of collective motions that may be
essential for PrPC-ligand interactions. The protomers were bound to the binding region I
(Figure 6.4 B). The simulation protocol was the same as for the free protein. For the three
ligands, the gaff force field (241; 242) was used. The atomic restrained electrostatic potential
(RESP) charges (23; 64) were calculated by using the resp module of AMBER after geometry
optimization and electrostatic potential calculations of each protomer at the B3LYP/6-31G**
level of theory by means of the g03 software (85).
6.2.3 Dissociation free energy calculations.
The dissociation free energies of 10, 1+ and 12+ were calculated using metadynamics (141) in its
bias-exchange variant (191), as a function of collective variables (CVs) which should be relevant
for describing the dissociation process. CVs used in this work are: (i) the distance between the
center of mass of the ligand and the center of mass of the protein binding region; (ii) the number
of polar contacts between the ligand and one portion of the protein binding region I; (iii) the
number of polar contacts between the ligand and the other portion of the protein binding region
I; (iv) the number of water bridge contacts between the ligand and the protein binding region I;
(v) the RMSD difference of the system with respect to an equilibrated MD structure taken from
the previous Section; (vi) the RMSD fluctuation of the residues defining the protein binding
region I. The choice of these CVs was based on previous ligand-target interaction metadyamics
studies (33; 82; 87; 232) as well as by observations based on the former MD simulations (see
Appendix E for more details). The calculations do not require in principle the previous knowl-
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edge of the protein-ligand adduct structure. However, for computational efficiency we exploit
the fact that all the target regions detected from NMR are in the close proximity of region I.
Therefore, here we explored only this region. Six independent metadynamics simulations were
run in parallel. Each replica was biased by different one-dimensional time-dependent poten-
tials, which were built as a function of each of the collective variables defined above. Exchanges
among replicas were attempted every 10 ps using a metropolis acceptance criterion (191). Sim-
ilar set-up was shown to improve the sampling of the configurational space and the convergence
of the results (148; 159; 191; 192; 226). At the end of the different replica simulations, the
explored phase space, in terms of the six collective variables used in this study, was clustered
using the gromos method (67). The clustering radius for each collective variable was set to 0.1
nm, 0.2, 0.4, 2.5, 0.05 nm, 0.02 nm, respectively. The free energy corresponding to each cluster
was then reconstructed from the populations of clusters observed during the simulations. The
free energy value was corrected by the corresponding bias potentials acting on that cluster as in
a usual weighted histogram analysis (39). Details on this procedure can be found in references
](148; 159; 192; 226), and are summarized in SI together with the converged free energy profiles.
Two reference states of the ligand-protein system, bound and unbound, needed to be defined
to provide the corresponding dissociation free energy value. The bound state was considered
as the lowest free energy cluster. The unbound state was considered to be a cluster showing no
contacts with the binding regions I (lowest values of CVs ii and iii) and at the same time with
a higher RMSD with respect to the initial docked structure (highest value of CV v). Given
the size of the simulation box the ligand is not fully detached from the protein in its unbound
state. Therefore, the residual dissociation energy of the unbound state was roughly estimated in
implicit solvent using an adaptive Poisson Boltzmann solver. The APBS package (18) was used
with the same parameters described previously. It was estimated as the difference in solvation
energy of the complex minus the solvation energy of each component plus the intermolecular
Coulomb interaction. The standard free energy of dissociation was obtained by applying the
following relationship: ∆ G0=∆G RT*ln([L]), where ∆G is the total dissociation free energy
as a result of our simulation, R is the molar constant, and [L] is the concentration of the ligand
in our simulation box (i.e. 5.5 mM, corresponding to 1 molecule in 6.693 nm3). The standard
free energy is related to the dissociation equilibrium constant (Kd) by ∆ G0 = RT*ln(Kd).
6.3 Results and Discussion
In this study, we focus on the binding of compound1to the surface of HuPrPC protein. Com-
pound1is a symmetric molecule, composed of two pyrrolidine rings connected by acetamides to
a diphenylmethane core (Figure 6.2). Two different conditions are considered: at neutral pH,
where experimental affinity has been measured (140) and at acidic pH, where NMR chemical
shift perturbations (140) have been used to provide information on the amino-acids involved in
the binding.
We use the computational protocol summarized in Figure 6.1: (i) Identification of ligand
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protonation state at neutral and acidic pH. (ii) Use of MDPs to provide a first guess of putative
binding regions (iii). Use of molecular dynamics (MD) simulations to relax the structure in
aqueous solution (step 1 in EMD). (iv) Use of metadynamics to predict the energetics of binding
of1to the protein as well as (v) the binding poses of the compound (step 2 in EMD).
Protonation state of compound 1. This compound can exist in different protona-
tion states, in which none, one or both the tertiary nitrogen atoms of the pyrrolidine rings are
protonated (Figure 6.3). At pH=7.4, at which the Kd has been measured, approximate pKa
calculations based on ref. 31 (See Methods for details) allow us to suggest that, in water,1
is present mainly not only in the neutral form (10) but also in the monoprotonated one (1+)
(Figure 6.3). In the latter, one of the two pyrrolidine nitrogen atoms is protonated.
At pH=4.5, at which the NMR experiments were performed, the same calculations lead us
to the conclusion that, in water, the ligand is mainly diprotonated (12+), with both pyrrolidine
nitrogen atoms protonated. Small amounts of 1+ are also present. The calculated concentration
of 10 in bulk water is very low (Figure 6.3). However, one should keep in mind that ligand-
protein binding does not occur in pure water and that the influence of the electrostatic field
of the protein should be accounted for. Indeed, simple electrostatic potential calculations (see
Methods for further details) show an increase of the positive charge density in the region of
the protein defined by the NMR contacts (Figure E.2 in Appendix E). This suggests that the
protein environment will favor there the accumulation of neutral 10. Therefore, binding poses
involving the neutral form should be considered even at acidic pH. Based on these results, we
performed calculations on all of the three protomers.
Binding regions of HuPrPC emerging from MDP. The three protomers were
docked independently to the HuPrPC NMR structure and to 20 different conformers obtained
from a 20-ns molecular dynamics (MD) simulations of the protein in aqueous solution. The
putative binding regions I, II and III were identified (Figure 6.4 B). I is defined by the H2
helix and the loop connecting β-sheet S2 and helix H1. II consists of the H2-H3 helices. III is
defined by the H3 helix, the N-term of H2 helix, and the loop between H1 helix and S1 β-sheet.
Binding region I is the only site which involves residues changing chemical shifts upon binding
of compound1and it is closer to all the other residues involved in the binding (140). It was
therefore the only one selected for subsequent free energy studies.
∆δ > 0.9ppm 0.9ppm > δ > 0.5ppm
Asn159 Arg156
Val189 Glu196
Thr192 Thr199
Lys194 Val210
Table 6.1: NMR chemical shift -NMR chemical shift changes (δ) upon GN8
binding to the MoPrPC
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Figure 6.4: Binding Regions - (A) Residues involved in GN8 binding to the
prion protein (in licorice), as emerging from chemical shift changes (140). (B) Three
different binding regions (I, II and III, shown in blue, red and yellow, respectively),
as obtained after MDP procedures (see Figure 6.1). Orange spheres represent
compound 1 binding aminoacids defined by NMR chemical shift study. The Figure
shows HuPrPC . This is very similar to the MoPrPC (Sequence Similarity = 98
% ), for which experiments have been carried out.
The adducts for each of the three protomers docked at binding region I underwent 10ns
of MD calculations in aqueous solution. The ligands maintained completely (1+ and 12+) or
partially (10) the pose identified in the docking (See Appendix E for details). Most importantly,
the structural determinants of the three protomers turned out to be consistent with most ligand-
protein contacts identified by NMR (Table 6.1 ). However, the ligand-protein contact with
Val189, Thr192, Thr199 and Val210 could not be predicted. The simpler docking approach,
combined with energy minimization of protomer 10 provided similar results (Figure. 3 in
Kuwata et al. (140) ).
Free energy calculations were used to explore the ligand binding space
in explicit solvent These simulations allowed to identify alternative binding poses for
each protomer of the ligand and, for 10 and 1+ , to predict the dissociation free energy. The
free energy simulations were performed as a function of 6 collective variables that took into
account rearrangements of the ligand and protein, hydrogen bond contacts and water bridges
(see Methods). These variables have been already used to characterize ligand-target molecular
recognition processes using the metadynamics approach (33; 82; 87; 232).
The HuPrPC-10 complex. In the lowest free energy cluster identified by the meta-
dynamics calculations, 10 is located in the wide cleft formed by helices H1, H2 and H3 (10.B1
in Figure 6.5 A), similarly to the model proposed by Kuwata et al. for MoPrPC (140). The
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Figure 6.5: Three dimensional structures of HuPrPC in complex with
1 protomers - (A) 10, (B) 1+ and (C) 12+. These structures correspond to the
bound-states free energy minima (10.B1, 1+.B1-B4, 12+.B1-B5), as calculated with
the metadynamics method (see Methods). Close-ups on the ligands and the binding
sites are also shown.
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contacts 10 forms with the HuPrPC are consistent with the reported chemical shift changes on
Glu196, upon GN8 binding (Table 6.1 ), as well as with a recent quantum chemical study (116).
They are also consistent with chemical shift changes on Arg156, Thr199, and Val210 upon GN8
binding (Table 6.1 ). The phenyl groups of 10 form a pi -cation interaction with Arg156 and
a water-mediated H-bond is present between Thr199 and the pyrrolidine nitrogen (N1; Fig-
ure 6.2). The pyrrolidine ring forms hydrophiobic interactions with Val210 (as well as with
Pro158, Thr183). The HuPrPC-10 complex is further stabilized with a direct H-bond between
Thr190 and the carbonyl group of 10 (O2; Figure 6.2). The unbound state of HuPrPC-10
system corresponds to a conformation in which the ligand has no contact with the protein. The
conformation of Lys194 changes upon ligand dissociation (Figure 6.6).
Figure 6.6: Lys194 - Ramachandran plot of residue Lys194 for the three adducts:
Crosses indicate the conformation of the residue when the ligand is bound, and
empty squares when the ligand is not bound.
This is consistent with the significant chemical shift change reported for this amino acid
(140). This contrasts with a recent quantum chemical investigation, which points to the role
of Lys194 for the bridging conformation of the GN8/PrPC complex (116). This discrepancy
may be due to the fact that here we consider free energies in solution, whilst ref. 20 presents
interaction energies in vacuo. Smaller conformational changes were also observed for other
residues present in the H2-H3 loop (res. 195-199 Appendix E, Figure
The HuPrPC-1+ complex. Four different stable conformations of 1+ were iden-
tified on HuPrPC surface (Figure 6.5 B). In the lowest free energy state, 1+ lays along the
loop connecting helices H2 and H3 (1+.B1 in Figure 6.5 B). It forms a remarkable hydrophobic
interaction with Thr199, consistently with the chemical shift changes reported for this residue
(140). The amidic nitrogen atoms of 1+ (N3 and N4; Figure 6.2) are H-bonded to Thr201 and
Asn197, respectively. This induces a subtle conformational change of the Glu196 and Asn197
backbone upon ligand binding which may be the reason for the chemical shift displacement
reported experimentally for Glu196 (Table 6.1 ). Additionally, the neutral pyrrolidine ring of
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1+ is kept by the hydrophobic cleft formed by Ile184, Thr188, Phe198, Val203 and Met206
further stabilizing the complex. No water-mediated interactions were observed between 1+ and
HuPrPC . The free energy difference between the bound state of HuPrPC-1+ (1+.B1 in Fig-
ure 6.5 B) and the corresponding unbound state, with the corrections described above, turns
out to be 8.6 kcal/mol. This is similar to that predicted for 10 and in good agreement with
experimental data.
The HuPrPC-12+ complex. Five different stable conformations of 12+ were iden-
tified on HuPrPC surface (Figure 6.5 C). In the most stable conformation, 12+ binds yet in
another position of HuPrPC , laying along helix H2 (12+.B1 in Figure 6.5 C). Half part of 12+
is in close contact with HuPrPC surface in the cleft formed by Val189, Thr192 and Thr193.
Indeed, these positions were reported to interact directly with the ligand according to NMR
experiments (Table 6.1 ). Two layers of water molecules are present between the protein sur-
face and the rest of the molecule, presumably due to the presence of Lys185. In the other
accessible conformations, 12+ covers different regions of the protein surface (See Appendix E).
The interaction with Lys194 is conserved in the majority of them. This result is consistent
with the chemical-shift changes of this residue upon ligand binding (140). The dissociation free
energy of 12+ was not calculated as, according to our calculations based on pKa estimations,
this protomer is not present at the conditions in which the Kd was measured (140).
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TSEs arise with the post-translational conversion of the ubiquitous cellular form of the prion
protein, PrPC , into its pathogenic form, PrPSc, without any detectable covalent modifications.
There is evidence that the PrPC → PrPSc conversion initiates an autocatalytic reaction, which
leads to the accumulation of amyloid in the central nervous system and, through still unknown
mechanisms, to neurodegeneration (147; 238; 240).
In the presence of pathogenic mutations, the PrPC → PrPSc conversion occurs sponta-
neously (13; 220; 223). Therefore these mutations might increase the likelihood of misfolding
by thermodynamic destabilization of PrPC (13; 220) (Fig. 1.2) 1
In this thesis, we have investigated PrPC disease-linked variants and the adduct with a
ligand by molecular simulation methods. Our goal has been to characterize the influence of
disease-linked mutations on the structural determinants as well as to build up a computational
protocol able to predict poses and energetics of ligands binding to PrPC .
First, we have focused on the destabilizing effect of all pathogenic mutations on PrPC
globular domain in the early stage of the conversion.
MD calculations, based on the NMR structure(247), reproduce the structural determi-
nants of HuPrP(E200K) (252) mutant and HuPrP(Q212P), (115), for which NMR structural
information are available. This establishes the reliability of our computational protocol. Our
calculations are then carried out on all of the pathogenic mutants of PrPC globular domain
(overall 28 variants, Fig. 5.1). All the variants turn out to features common traits, indepen-
dently from position and chemical nature of the mutations. These features are: (i) an increase
of the flexibility of the β2-α2 loop, of the α2-α3 region and a larger solvent exposure of Tyr169
(which belong to the β2-α2 loop) relative to the wild type prion protein. Strikingly, the flex-
ibility of β2-α2 and α2-α3 is related to pathogenicity of TSEs (2; 45; 54), and it might also
affect the interactions of PrPC with cellular partners during fibrillation (124; 225). Indeed,
the β2-α2 loop and parts of helix α3 form an epitope that might serve as recognition site for
1Remarkably, a class of antiprion compound has been discovered which may act stabilizing
PrPC structure (30).
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a potential chaperone assisting PrPC →PrPSc conversion (124). In this respect, also the re-
arrangement of Tyr169 exposure might play a crucial role for fibrillation. Its exposure toward
the solvent modifies the hydrophobic surface of the protein and alters pi-staking interactions
in the recognition site. Remarkably, in all of the pathogenic mutants with high incidence on
the population (namely HuPrP(E200K) (HuPrP(V210I), HuPrP(D178N-129M) (134), Tyr169
features the largest degree of solvent exposure. In addition, part of helix α3 is opened and
accessible to solvent (Fig. 5.2).
We thus identify some hot spots in PrPC structure, rather sensible to mutations that
could give crucial hints in understanding the early stage of PrPC → PrPSc conversion. The
knowledge of PrPC regions most susceptible to the effect of pathogenic mutations might provide
important hints for a molecular-based drug design approaches (228).
Next, I have contributed to the development of a docking procedure able to characterize
binding of small ligands on shallow binding sites, where multiple binding pose are possible, such
as in the case of prion protein. This is challenging for standard molecular docking procedures,
which might encounter difficulties in ligands binding to (multiple) shallow binding sites. We
further notice that in docking procedures which take into account protein flexibility, (11; 36;
47; 227), probably very important here, might provide a significant number of false-positive
solutions (11).
Here, we have established a computational approach that combines standard docking meth-
ods with molecular dynamics and metadynamics-based free energy simulations (141) (Fig. 6.1).
We have focused on a specific ligand (2-pyrrolidin-1-yl-N-[4-[4-(2-pyrrolidin-1-yl-acetylamino)-
benzyl]-phenyl]-acetamide), which may stabilize PrPC , binding to the structured part of the
protein (as shown by NMR (141)).
Our procedure is able to account for protein flexibility and it provides detailed information
about the binding process, binding affinity and ligand-target interactions. Applying our pro-
cedure on PrPC , we found a multiple-pose binding pattern for the examined compound that
could not be obtained by applying only standard protocols. Three binding poses are identified,
in complete agreement with NMR data (140). Most importantly, the predicted dissociation free
energy turned out to be in very good agreement with experimental data (140).
Our protocol could be now used to predict the potency of ligands interacting on protein
surfaces or with target proteins without a unique binding site. These include most proteins
involved in neurodegeneration possessing a structured moiety (20; 51; 81; 104; 175; 221; 229).
84
List Of Publications
Papers related to the thesis:
G. Rossetti, G. Giachin, G. Legname, P. Carloni, Structural facets of disease-linked human
prion protein mutants: A molecular dynamic study Proteins, (Jul 23, 2010).
A. Kranjc, S. Bongarzone, G. Rossetti, X. Biarnes, A. Cavalli, M. L. Bolognesi, M.
Roberti, G. Legname, P. Carloni, Docking Ligands on Protein Surfaces: The Case Study of
Prion Protein J. Chem. Theory Comput. 5, 2565 (Sep 8, 2009).
Other papers:
G. Rossetti, A. Magistrato, A. Pastore, P. Carloni, Hydrogen Bonding Cooperativity in polyQ
-Sheets from First Principle Calculations Journal of Chemical Theory and Computation 6, 1777
(Jun 8, 2010).
G. Rossetti, A. Magistrato, A. Pastore, F. Persichetti, P. Carloni, Structural properties
of polyglutamine aggregates investigated via molecular dynamics simulations J Phys Chem B
112, 16843 (Dec 25, 2008).
D. Flock, G. Rossetti, I. Daidone, A. Amadei, A. Di Nola, Aggregation of small peptides
studied by molecular dynamics simulations Proteins 65, 914 (Dec 1, 2006).
85

Appendix A
Human Prion Diseases
A.1 Human Prion Diseases
Prion diseases are also referred as transmissible spongiform encephalopathies (TSE). They
occur in humans and animals, primarily affecting the central nervous system. They can be
sporadic (spontaneous), familial (genetic/inherited) or acquired (transmitted by infection). The
hallmark of these diseases is the presence of microscopic vacuolization of the brain tissue, called
spongiform degeneration (meaning that the tissue deteriorates, developing a spongy texture),
and an abnormal protein, called scrapie prion protein (PrPSc), prion or abnormal prion protein.
Humans are susceptible to several prion diseases that include:
- CJD: Creutzfeld-Jacob Disease.
- GSS: Gerstmann-Straussler-Scheinker syndrome
- FFI: Fatal familial Insomnia.
- Kuru
These original classifications were based on a clinical evaluation of a patients family history
symptoms and are still widely used, however more recent and accurate molecular diagnosis of
the disease is gradually taking the place of this classification. The incidence of sporadic CJD
is about 1 per million per year. GSS occurs at about 2% of the rate of CJD. It is estimated
that 1 in 10,000 people are infected with CJD at the time of death. These data are likely to be
underestimates since prion diseases may be misdiagnosed as other neurological disorders. The
diseases are characterized by loss of motor control, dementia, paralysis wasting and eventually
death, typically following pneumonia.
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A.1.1 Polymorphisms
All prion disease, inherited forms, iatrogenic or sporadic, are influenced by an aminoacis poly-
morphism 1 resulting in a Methionine (M) to Valine (V) substitution at PrP codon 129 (184).
This polymorphism is crucial to the etiology and neuropathology of prion disease; it is
found that homozygosity at codon 129 predisposes individuals to CJD (186) and to date, only
individuals homozygous for methionine (Met/Met) have succumbed to variant CJD (60; 108),
and iatrogenic CJD occurs predominately in homozygotes with an excess of valine homozygotes
in cases related to exposure to contaminated human pituitary hormones (62).
The importance of sequence homology is further emphasized by the observation that in
some families with inherited prion diseases, the age of onset is significantly later in individuals
heterozygous to this polymorphism (61; 75; 195). Thus, heterozygosity with respect to this
polymorphism appears to confer substantial resistance to prion disease.
Elderly survivors of the kuru epidemic (an acquired prion disease largely restricted to
the Fore linguistic group of the Papua New Guinea Highlands, which was transmitted during
endocannibalistic feasts) who had multiple exposures at mortuary feasts, are, in marked contrast
to younger unexposed Fore, predominantly PRNP 129 heterozygotes. Kuru imposed strong
balancing selection on the Fore, essentially eliminating PRNP 129 homozygotes.
Worldwide PRNP haplotype diversity and coding allele frequencies have suggested that
strong balancing selection at this locus occurred during the evolution of modern humans (165).
A second polymorphism resulting in glutamate (E) to lysine (K) substitution at codon 219
has been identified in the Japanese population, and it has also been reported to have an effect
on the susceptibility of individuals to prion disease (128).
A.1.2 Inherited Prion Diseases
Familial TSEs are associated with an autosomal dominant 2 PRNP gene alteration. Depending
on the particular PRNP mutation involved, there is variability in the clinical and pathological
findings, the age of onset, and the duration. Familial TSEs account for 1020% of all TSE cases
in humans and include fCJD, GSS, and FFI.
The clinical categories may be seen as phenotypic extremes of a continuum (5), because in
reality the syndromes overlap considerably (165).
fCJD have been associated with point mutations affecting the region between the second
1Polymorphism is a discontinuous genetic variation that results in different forms or types of
individuals among the members of a single species. Genetic polymorphism promotes diversity
within a population. It often persists over many generations because no single form has an
overall advantage or disadvantage over the others regarding natural selection. A common
example is the different allelic forms that give rise to different blood types in humans.
2Autosomal dominant is one of several ways that a trait or disorder can be passed down
through families. If a disease is autosomal dominant, it means you only need to get the abnormal
gene from one parent in order for you to inherit the disease. One of the parents may often have
the disease.
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and the third helix of the C terminus region, insertions in the octarepeat region, in the N
terminus, and even a premature termination codon at position 145. The inheritance is, in all
cases, autosomal dominant, often with very high penetrance (133).
GSS syndrome is a rare, inherited autosomal dominant disease that is associated with
mutations in the PRNP gene. GSS syndrome is characterized by chronic progressive ataxia,
terminal dementia, a long clinical duration (210 yr), and multicentric amyloid plaques that can
be visualized by antibodies directed against the prion protein.
FFI is characterized by sleep disturbances as well as vegetative and focal neurological signs
as a result of thalamic lesions. The clinical phenotype depends on the D178N point mutation
of the PRNP gene coupled with a methionine at codon 129.
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Biophysical Mechanisms of Prion
Toxicity
B.1 Models describing the replications of prions
According to the protein only hypothesis, there are at least two models to explain the confor-
mational conversion of PrPC into PrPSc and prion propagation:
- The heterodimer refolding mechanism, also known as template-assistance model or monomer-
directed conversion (198);
- The nucleated polymerization mechanism (117).
These models differ with respect to the role of ordered prion protein oligomers in the
conversion reaction.
The heterodimer refolding mechanism model postulates that PrPC is thermodynamically
less stable than PrPSc but spontaneous conversion to PrPSc is kinetically limited. A critical
step in the conversion would be the formation of a heterodimer between PrPC and PrPSc
monomers. PrPSc in this complex would act as a template, inducing a conformational transition
of PrPC . Here, oligomerization is a consequence, not a cause, of conversion.
A different view is presented by the nucleated polymerization mechanism model, according
to which the infectious species is not the PrPSc monomer but a PrPSc aggregate. This model
postulates that monomeric PrPC and PrPSc exist in an equilibrium far displaced toward
PrPC . Stabilization of PrPSc occurs only upon formation of an oligomer large enough to
act as a stable nucleus. Monomeric PrPC would subsequently add to the nucleus, adopting
the structure of PrPSc. The rate-limiting step in the nucleated polymerization model is not
conversion but nucleation. This step, responsible for the lag phase in the spontaneous conversion
reaction, can be bypassed by addition of preformed PrPSc aggregates.
While both these mechanisms are theoretically plausible, there is little evidence for the
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existence of a stable PrPSc monomer. Moreover, prion infectivity is associated with PrPSc-
containing aggregates, not with PrP monomers (213).
B.2 Cell-Free Conversion Studies.
An important development in TSE research was the finding that PrPC can be converted in
vitro into a PrPSc-like conformation (a protease-resistant state, PrP-res) from infected animals
with normal PrPC (42; 111; 131).
These cell-free experiments, pioneered by Caughey and co-workers, demonstrated that PrP
conversion consists of two kinetically distinct steps: (i) binding of PrPC to PrP-res oligomer,
followed by (ii) conversion of bound PrPC to the PrP-res conformation.
In this in vitro conversion, formation of new PrP-res molecules invariably required the
presence of oligomeric seeds, and the newly created PrP-res always remained tightly associated
with the original PrP-res, indicating that aggregation is an inseparable aspect of PrP conversion
(42; 111; 131).
This arguing against the existence of a stable -sheet-rich monomer of PrP
B.3 Recombinant Prion Protein.
Since biophysical studies with brain-derived PrP pose major experimental challenges, many lab-
oratories have resorted to bacterially expressed recombinant prion protein (rPrP), which can be
readily purified in large quantities. Although the recombinant protein lacks both glycolsylation
and the GPI anchor, its secondary and tertiary structures appear to be identical to those of
brain-derived PrPC (113).
Thus, rPrP provides a useful tool for studying the physiochemical properties and confor-
mational transitions of the prion protein (220).
Early studies revealed that the transition of the human rPrP (fragment 90-231) to an
oligomeric -sheet structure is especially effective at mildly acidic pH and in the presence of low
concentrations of chemical denaturants (222). Moreover, the α-helix to β-sheet transition occurs
concomitantly with oligomerization of the protein, according to cell-free conversion studies.
(222) However, the α-helix to β-sheet conversion reaction described in these early studies was
non-autocatalytic, failing to mimic self-propagation of infectious prions.
Auto-catalytic (seeded) conversion of rPrP was first generated by disulfide oxidation and
reduction (146), leading to a model of prion propagation based on the domain-swapped structure
as observed in a crystallographic study with human rPrP (130). There is, however, no evidence
that disulfide reshuﬄing occurs during PrPC to PrPSc conversion in vivo. More recently, it
was shown that rPrP can be converted to classical amyloid fibrils without the reduction of the
native disulfide bond (21) and in the absence of any denaturing agents or detergents (56).
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B.3.1 Synthetic Prions
Intracerebral injection of recombinant PrP fibrils into transgenic mice over expressing N-
terminally truncated PrPC was reported to result in a transmissible neurological disorder,
though characterized by a very long incubation time as compared to those of classical TSE
diseases (147). This observation has led to the conclusion that these aggregates represented
synthetic prions, associated with an unusually slow strain of the disease. While these findings
are undoubtedly significant, there are a number of unresolved questions pertaining to this study
(57).
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Table 3.A: Partial clusterization. RMSD values of the system studied respect the MD_WT 
structure. The structure chosen as the reference is the representative structure of the most 
populated cluster coming from our cluster analysis. 
 
Reference: NMR 
corresponding structure (nm)* 
 
 
Reference: MD_WT 
structure (nm) 
Folded-domain Non-loop 
MD_WT 0.14±0.05  0.11±0.01 0.09±0.01 
MD_WT 1 0.14±0.05 0.11±0.01 0.09±0.01 
MD_WT 2 0.12±0.03 0.12±0.03 0.09±0.01 
MD_WT 3 0.12±0.03 0.12±0.03 0.09±0.01 
MD_E200K 0.20±0.02 0.20±0.02 0.15±0.01 
MD_E200K 1 0.13±0.02 0.13±0.02 0.09±0.02 
MD_E200K 2 0.13±0.03 0.13±0.02 0.09±0.02 
MD_E200K 3 0.14±0.03 0.14±0.02 0.09±0.01 
MD_Q212P 0.17±0.02 Not available 
MD_Q212P 1 0.14±0.02 Not available 
MD_Q212P 2 0.15±0.02 Not available 
MD_Q212P 3 0.15±0.02 Not available 
MD_E219K 0.20±0.03 Not available 
MD_E219K 1 0.13±0.02 Not available 
MD_E219K 2 0.12±0.0.2 Not available 
MD_E219K 3 0.12±0.0.2 Not available 
*The reference structures used are: PDB code 1HJN (Calzolai et al. 2003, J Biol Chem) for the 
MD_WT set of simulations and PDB code: 1FO7 (Zhang et al. 2000, J Biol Chem) for MD_E200K 
set. 
 
Table 3.B: Total clusterization. RMSD values of the system studied resp ct the MD_WT 
structure. The structure chosen as the reference is the representative structure of the most 
populated cluster coming from our cluster analysis. 
 
Reference: NMR 
corresponding structure (nm)* 
 
 
Reference: MD_WT 
structure (nm) 
Folded-domain Non-loop 
MD_WT_tot 0.13±0.04 0.11±0.02 0.09±0.01 
MD_E200K_tot 0.15±0.03 0.15±0.02 0.09±0.02 
MD_Q212P_tot 0.16±0.03 Not available 
MD_E219K_tot 0.14±0.03 Not available 
 
 
 
Figure C.1: RMSD - RMSD values of the system studied respect the WT struc-
ture. The structure chosen as the reference is the representative structure of the
most populated cluster coming from our cluster analysis.
! "!
MD_E 19K 2 -----* 0.45±0.02 0.68±0.02 
MD_E219K 3 0.45±0.01 0.46±0.02 0.68±0.01 
 
*A different configuration forTyr169 is here observed. The 
residue lies between Tyr218 and Tyr225. See Figure on the 
side. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.B: Total clusterization. !-stacking and (Cys179-Cys214) bridge mean values for each set 
of simulations. 
 
Interaction !-stacking (Cys179-Cys214) bridge 
Systems Tyr169-Phe175 (nm) Phe175 - Tyr218 (nm) C"- C" (nm) 
MD_WT_tot 0.45±0.02 0.46±0.03 0.68±0.01 
MD_E200K_tot 0.87±0.10 0.48±0.03 0.65 ± 0.02 
MD_Q212P_tot 0.87±0.16 0.47±0.03 0.65 ± 0.02 
MD_E219K_tot 0.44±0.02 0.45±0.02 0.68±0.01 
 
 
 
 
 
 
 
 
 
 
 
 
Tyr169!
Tyr225!
Tyr218!
Figure C.2: pi -stacking and ( Cys179-Cys214 - pi -stacking and ( Cys179-Cys214)
bridge mean values for each set of simulations.
95
C. ADDITIONAL DETAILS ON CHAPTER 5
! "!
Table 4: Convergence  
System R=!Etot/!Ekin Average Etot (KJ mol-1)  Drift (KJ mol-1)  
MD_WT 0.048 -315260 -0.00217825 
MD_WT 1 0.048 -315220 -0.00218826 
MD_WT 2 0.043 -351255 0.000134186 
MD_WT 3 0.043 -351255 -0.00013589 
MD_E200K 0.054 -314972 -0.00514264 
MD_E200K 1 0.043 -317077 -0.0001443 
MD_E200K 2 0.045 -317105 -0.0007398 
MD_E200K 3 0.042 -317101 -0.0036171 
MD_Q212P 0.052 -314763 -0.00498458 
MD_Q212P 1 0.043 -314832 -0.0026909 
MD_Q212P 2 0.051 -314835 -0.0028808 
MD_Q212P 3 0.042 -314802 -0.00237203 
MD_E219K 0.057 -314331 -0.00572916 
MD_E219K 1 0.052 -314399 -0.00253388 
MD_E219K 2 0.041 -314384 -0.00215787 
MD_E219K 3 0.0542 -314400 -0.00090530 
 
 Figure C.3: Convergence - Convergence
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TSEs susceptibility
TSEs susceptibility has been correlated both with the aminoacidic composition of the β2-α2
loop and with long-range interactions between residues in the β2-α2 loop and residues at the
C-terminal of the 3 helix (54). Indeed, within the highly conserved PrP scaffold 1, the β2-α2
loop residues (165-173, in human numbering) show local structure variations among species.
Figure D.1: β2-α2 loop in different species - Polypeptide segment 162174
in the energy-minimized NMR structures (92) and multiple sequence alignment of
162-174 residues of PrPC in different species (182)
The NMR-derived flexibility of the loop of PrPC in mouse, sheep and syriam hamster, for
which prion disease cases have been reported is larger than that in PrPC of elk (92), bank vole
(55), tammar wallaby (54) and, very recently, horse (Perez et al. available on line). Interestingly,
in contrast to elk and bank voles, which have a well-defined β2-α2 loop (55; 92), and which have
independently been shown to be highly susceptible to TSE infection, no TSE has been reported
so far in marsupials nor in horses (3; 178). Christen et al. (54) show that the high structural
1Sequence Identity of the examined Species across the globular domain is very high 97 %
or more
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definition of the β2-α2 loop in tammar wallaby and horse PrP is entirely due to long-range
interactions between loop residues and C-terminal part of 3 (54; 55), whereas in the PrPs of
elk and bank vole, the high structural definition of the loop is related to apparently strictly
local effects from amino acid substitutions within the loop (55; 92). Thus, the results of the
NMR studies on the examined species (3; 55; 92; 178)(Perez et al. available on line), imply
that plasticity of the epitope formed by the β2-α2 loop and helix 3 appears to determine the
susceptibility of a given species to development of a TSE, rather than the isolated β2-α2 loop
conformation.
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Additional details for the PrP
docking protocol
E.1 Details on Molecular Docking
Molecular docking is a computational procedure that predicts binding mode of a ligand in its
target protein. This is achieved by minimizing a scoring function which describes the interac-
tions between ligand and target with respect to the atomic positions of the to moieties. In this
work, GOLD (121; 234) and the Autodock programs (171) were used to predict ligand-protein
interactions.
E.1.1 Ligand-protein docking
GOLD (Genetic Optimization for Ligand Docking) (121; 234) is a program used for docking of
small flexible compounds to the protein binding site. GOLD uses an island-based GA search
strategy and includes rotational flexibility for selected receptor hydrogen along with full ligand
flexibility. It has two implemented scoring functions, GoldScore and ChemScore, and a possi-
bility for user dened scoring function. In this work GOLD 3.0.1 was used. AutoDock (171) uses
a genetic algorithm as a global optimizer combined with energy minimization as a local search
method. The ligand is flexible, while the receptor is rigid.
E.1.1.1 Search Algorithms
The search of a pose of a ligand in a docking problem is addressed in two essentially different
approaches: (1) a full solution space search (2) a gradual guided progression through solution
space. The first scans the entire solution space in a predened systematic manner (103). In
contrast, the second either scans only part of the solution space in a partially random and
partially criteria-guided manner, or generates fitting solutions (103). The second approach
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consists mainly of Monte Carlo (MC), simulated annealing, molecular dynamics (MD), and
evolutionary algorithms such as genetic algorithms (GA) and Tabu search. The two docking
programs used in this work, GOLD and AUTODOCK, search for optimal ligand binding modes
inside a specific binding pocket using a genetic algorithm (89; 109).
Genetic Algorithms Genetic algorithms (GA) (89; 109) are based on the language of
natural genetics and biological evolution. They search for possible ligand binding modes by
representing the ligand conformations in a modular way, using operations similar to mutations
and crossover. The quality of the results is a function of the starting genes, the number of evo-
lutionary events, i.e., the mutations and crossover, and the scoring function to pick the more
favourable conformers. The GA begins with an initial population, that is a set of chromosomes
(ligand binding modes, chosen randomly). Chromosomes are defined by genes (variables) corre-
sponding to the ligand translation (x, y, z coordinates of the center of mass), ligand orientation
(rotation angles) and ligand conformation (torsion angle of each ligand rotatable bond). The
population goes through a process of fitness evaluation: each chromosome is assigned a score
based on a function which approximately estimate the free energy of binding. Once the initial
population is evaluated, two chromosomes are selected as parents and starting from them a
new population is built. A probability to become parent chromosome grows with the fitness
score. The offspring chromosomes are obtained by a crossover and/or mutation processes on
the parent chromosomes. In crossover the chromosomes of the parents are broken into two
pieces at the same gene positions, then the first part of one chromosome is combined with
the second part of the other chromosome, and viceversa, resulting in two children. Mutations
randomly modify one or more selected gene(s) in the offspring chromosomes. The new children
replace their parents in the population that enters a new run of algorithm. The whole cycle is
repeated until some number of generations are completed or until some condition (RMSD, δG)
is satisfied.
Island-based genetic algorithm In GOLD a so-called island-based genetic algorithm
is employed. It means that rather than manipulate only one large population of chromosomes
(as described in previous Section), several subpopulations (i.e. islands) are considered and
individual chromosomes can migrate among them. This feature improves efficiency of the
search. In addition, information about hydrogen bonds between ligand and receptor is also
encoded in the chromosome. The ligand-receptor hydrogen bonds are matched with a least
squares fitting protocol to maximize the number of inter-molecular hydrogen bonds.
Lamarckian genetic algorithm The Autodock uses a genetic algorithm in which
is implemented a local search method that allows to minimize the scoring function of selected
individuals. The optimized atomic coordinates (phenotype) are stored back in the chromosome.
The new chromosome enters then into the new iteration of crossover and mutation of the genetic
algorithm. Due to the transfer of information from phenotype to chromosome this algorithm
is called Lamarckian. 2.1.2 Ranking of the solutions - Scoring functions Scoring functions
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estimate the energetics associated with ligands binding to their target. The purpose of the
scoring function is to discriminate between correct native solutions with low RMSD from the
crystal and other docked complexes within a reasonable computation time. Although scoring
functions may be formally dened as free energies, here they are only used to predict ligand
binding poses.
E.1.1.2 GOLD scoring functions
The GOLD program has implemented two scoring functions, ChemScore (CS) (177) and Gold-
Score (GS) (121). The ChemScore scoring function was parametrized against experimental
binding affinities data and gives as a result estimated binding affinity of the docked ligand. The
ChemScore scoring function estimates the total binding free energy as a sum of different compo-
nents (hydrogen bonding, metal and lipophilic interactions and loss of conformational entropy
of the ligand upon binding). The final ChemScore value is obtained by adding in a clash penalty
and internal torsion terms, which militate against close contacts in docking and poor internal
conformations. Covalent and constraint scores may also be included. The GoldScore scoring
function is calculated as a sum of the protein-ligand hydrogen-bond energy, the protein-ligand
van der Waals energy, the ligand internal van der Waals energy and ligand torsional strain en-
ergy. The contribution of ligand intramolecular hydrogen bonds can be added. ChemScore and
GoldScore are about equally reliable. However, based on our experience, ChemScore performs
better when lipophilic interaction between the ligand and receptor are prevalent, while Gold-
Score gives better results for the complexes between the polar ligand and receptor (hydrogen
bond interactions).
E.1.1.3 Autodock scoring function
In AutoDock the implemented scoring function is defined as an empirical binding free energy
function.The are three terms in vacuo, namely Lennard-Jones dispersion, directional hydrogen
bond and screened Coulomb electrostatic potential. Then there is a term which is a measure
of the unfavorable entropy of ligand binding due to the restriction of conformational degrees
of freedom. Finally, the last term approximately accounts for the desolvation free energy upon
ligand binding. For each atom in the ligand, fragmental volumes of surrounding protein atoms
are weighted by an exponential function and then summed, evaluating the percentage of volume
around the ligand atom that is occupied by protein atoms. This percentage is then weighted
by the atomic solvation parameter of the ligand atom to give the desolvation energy.
101
E. ADDITIONAL DETAILS FOR THE PRP DOCKING
PROTOCOL
E.2 Details of MD of GN8 protomers in com-
plex with HuPrPC.
The GN8-HuPrPC adducts that emerged from docking calculations underwent 10ns of molec-
ular dynamics (MD) simulations in aqueous solution. The ligands maintained completely (1+
and 12+) or partially (10) the poses identified in the docking. After 3ns of MD simulations,
10 partially slided out of the binding pocket. In its final conformation, the GN8 amide oxygen
(O2, Figure 1) forms H-bond interactions with Lys194. The pyrrolidine ring forms hydropho-
bic interactions with methylene groups of Glu196 and Arg156. The two aromatic rings form
also hydrophobic interactions with the methylene groups of Lys194. Water molecules can be
involved in protein-ligand recognition by forming mediated H-bonds between the protein and
the ligand. In this regard, water-mediated H-bond contacts were identified between HuPrPC
and protomers during the MD simulations. The amidic nitrogen of 10 protomer forms water
mediated H-bond with carbonyl oxygen of Arg156, with hydroxyl group of Thr190 or imidazole
nitrogen of His187. Instead, 1+ and 12+ kept their initial docked structure during the MD.
The amide nitrogen atom of both protomers (N3; Figure 1) H-bonds to the backbone oxygen
of Glu196. The carbonyl oxygen (O5, Figure 1) of 1+ H-bonds to the backbone amino group
of Asn159. In addition, phenyl rings of 1+ form hydrophobic interactions with the methylene
groups of Arg156 and T-stacking interactions with the His187. During the MD the protonated
nitrogen atom (N1, Figure 1) of 1+ forms direct or water mediated H-bond with the carboxylate
side chains of Asp122. The protonated N6 atom of 12+ forms water mediated H-bond with the
side chain oxygen of Asn159. Electrostatic interaction is present among carboxylate of Glu196
and N1 atom of 12+. Hydrophobic interactions between the diphenylmetane fragment of 12+
and methylene groups of Lys194 and Arg156 stabilize further the binding of 12+.
E.3 Details of bias-exchange metadynamics sim-
ulations performed here.
In metadynamics (141) a history dependent potential that guides the evolution of the system
is constructed as a sum of Gaussian functions centered on the value of each collective variable
along the simulation. Here, a new Gaussian term was added to the historic dependent potential
every 1 ps. The metadynamics parameters of this bias potential were set up as our previous work
(28; 82; 232) (Tab. E.1). Here we have combined metadynamics with its bias exchange variant
(191). Six independent metadynamics simulations were run in parallel. Each replica was biased
by different one-dimensional time-dependent potential, which was built as a function of each
of the collective variable defined above. Exchanges among replicas were attempted every 10 ps
using a metropolis acceptance criterion (191). Similar set-ups have been shown to improve the
sampling of the configurational space and the convergence of the results (148; 191; 192; 226).
The different simulation replicas of the system were run for 30 ns each (total sampling time of
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180 ns). Along these simulations the ligand gets reversibly bound and unbound to different parts
of the protein surface. As in standard metadynamics, the replicas were allowed to run until the
different bias potentials were converged. To ensure the convergence of the bias potentials, two
average profiles were computed: one between times 15 ns to 22.5 ns and the other between times
22.5 ns to 30 ns. Only the portion of the two average profiles that agreed with each other within
1.5 kBT were used for further analysis. (see Figure E.1 A and B). An analysis of the converged
bias potentials together with the trajectories allows quantifying the relative free energy between
all the different states detected during the bias exchange metadynamics simulations. This
methodology is based on the weighted histogram analysis method (WHAM) introduced by
Kumar et al. (136). Details on this procedure can be found in references (148; 192; 226).
Briefly, the method is based on 1) clustering the phase space explored during the simulations
as a function of the collective variables, 2) evaluating the population of each cluster along each
biased trajectory, 3) assigning the unbiased free energy to each cluster by means of the WHAM
and using the information from the converged free energy profiles. Between 15ns and 30ns, the
trajectories of the different replicas were evolving under the action of converged bias potentials
(Figure E.1 A and B). Thus, only this part of the simulation data was used for extracting
statistical information.
collective variable width of the Gaussian height of the Gaussian
distance 0.02 0.04 nm 0.05 0.14 kcalmol-1
polar contacts A 0.1 0.2 0.05 0.14 kcalmol-1
polar contacts B 0.2 0.3 0.05 0.14 kcalmol-1
water bridges 0.8 1 0.05 0.14 kcalmol-1
RMSD system 0.01 0.02 nm 0.05 0.14 kcalmol-1
RMSD binding site 0.01 0.02 nm 0.05 0.14 kcalmol-1
Table E.1: Parameters of the biasing potential in the metadynamics
calculations.
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Figure E.1: Free energy profiles - Free energy profiles at the end of the sim-
ulation of (A) 10 and (B) 1+ protonation states as a function of each collective
variable. The portion of each profile that is converged at the end of the simulation
is highlighted in a bold line (For details see Methods).
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Figure E.2: Electrostatic potential - Electrostatic potential generated by
HuPrPC at different experimental conditions. Left: NMR measurements con-
ditions (pH=4); Right: Affinity measurements conditions (pH=7). Red volume
represents the regions at -1.2 eV; Blue volume represents the regions at +1.2 eV.
Center: Residues involved in GN8 binding to the prion protein (in licorice), as
emerging from chemical shift changes.
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